{
  "meta": {
    "id": "test6",
    "title": "Cardiovascular System",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "All the following drugs are used for treatment of congestive heart failure except:",
      "options": [
        {
          "label": "A",
          "text": "Nesiritide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sacubitril",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trimetazidine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Metoprolol",
          "correct": false
        }
      ],
      "correct_answer": "C. Trimetazidine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-094413.png"
      ],
      "explanation": "<p><strong>Ans. C) Trimetazidine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Nesiritide: Nesiritide is a recombinant B-type natriuretic peptide that has vasodilatory effects and is used in the management of acute decompensated heart failure.</li><li>\u2022 Option A. Nesiritide:</li><li>\u2022 recombinant B-type natriuretic peptide</li><li>\u2022 vasodilatory effects</li><li>\u2022 acute decompensated heart failure.</li><li>\u2022 Option B. Sacubitril: When combined with valsartan (a neprilysin inhibitor and an angiotensin II receptor blocker, respectively), sacubitril is used to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure.</li><li>\u2022 Option B. Sacubitril:</li><li>\u2022 combined with valsartan</li><li>\u2022 neprilysin inhibitor and an angiotensin II receptor blocker,</li><li>\u2022 reduce the risk of cardiovascular death</li><li>\u2022 hospitalization for heart failure in patients</li><li>\u2022 chronic heart</li><li>\u2022 failure.</li><li>\u2022 Option D. Metoprolol: Metoprolol is a beta-blocker that is used in the management of CHF. It reduces myocardial oxygen demand and can improve survival in patients with heart failure.</li><li>\u2022 Option D. Metoprolol:</li><li>\u2022 beta-blocker</li><li>\u2022 CHF.</li><li>\u2022 reduces myocardial oxygen demand</li><li>\u2022 improve survival in patients with heart failure.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "76a0acca",
      "audio": ""
    },
    {
      "text": "Angiotensin receptor blocker which blocks thromboxane A2 receptor is?",
      "options": [
        {
          "label": "A",
          "text": "Losartan",
          "correct": true
        },
        {
          "label": "B",
          "text": "Telmisartan",
          "correct": false
        },
        {
          "label": "C",
          "text": "Candesartan",
          "correct": false
        },
        {
          "label": "D",
          "text": "Olmesartan",
          "correct": false
        }
      ],
      "correct_answer": "A. Losartan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Losartan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Telmisartan: Incorrect because Telmisartan is known as a partial agonist of peroxisome proliferator-activated receptor gamma (PPAR-\u03b3), which differentiates it from Losartan and does not confer the ability to block the thromboxane A2 receptor.</li><li>\u2022 Option B. Telmisartan:</li><li>\u2022 Incorrect</li><li>\u2022 Telmisartan is known as a partial agonist of peroxisome proliferator-activated receptor</li><li>\u2022 gamma (PPAR-\u03b3),</li><li>\u2022 does not</li><li>\u2022 block the thromboxane A2 receptor.</li><li>\u2022 Option C. Candesartan: Incorrect as Candesartan is an inactive ester prodrug that does not possess the ability to block the thromboxane A2 receptor. It is hydrolyzed to its active form within the body, which acts selectively on the angiotensin receptor.</li><li>\u2022 Option C. Candesartan:</li><li>\u2022 Incorrect</li><li>\u2022 Candesartan</li><li>\u2022 inactive ester</li><li>\u2022 does not</li><li>\u2022 block the</li><li>\u2022 thromboxane A2 receptor.</li><li>\u2022 hydrolyzed</li><li>\u2022 its active form</li><li>\u2022 acts selectively</li><li>\u2022 angiotensin receptor.</li><li>\u2022 Option D. Olmesartan: Incorrect for this question since Olmesartan, while also being an inactive ester prodrug hydrolyzed to its active form , does not block the thromboxane A2 receptor. It is cleared by renal elimination and biliary excretion and does not require dose adjustment in patients with mild-to-moderate renal or hepatic impairment.</li><li>\u2022 Option D. Olmesartan:</li><li>\u2022 Incorrect</li><li>\u2022 Olmesartan,</li><li>\u2022 inactive ester prodrug hydrolyzed</li><li>\u2022 active form</li><li>\u2022 does not block the thromboxane A2 receptor.</li><li>\u2022 cleared by renal elimination</li><li>\u2022 biliary excretion</li><li>\u2022 does not</li><li>\u2022 mild-to-moderate renal or hepatic impairment.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Losartan is unique among angiotensin receptor blockers in that it also competitively antagonizes the thromboxane A2 receptor, contributing to its antiplatelet effects.</li><li>\u2022 Losartan</li><li>\u2022 angiotensin receptor blockers</li><li>\u2022 competitively antagonizes</li><li>\u2022 thromboxane A2 receptor,</li><li>\u2022 antiplatelet effects.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b776e021",
      "audio": ""
    },
    {
      "text": "A patient is taking atorvastatin for dyslipidemia. Which of these drugs should be avoided in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Clarithromycin",
          "correct": true
        },
        {
          "label": "B",
          "text": "Oxycodone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Rivaroxaban",
          "correct": false
        },
        {
          "label": "D",
          "text": "Adalimumab",
          "correct": false
        }
      ],
      "correct_answer": "A. Clarithromycin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Clarithromycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Oxycodone: Incorrect because oxycodone, an opioid analgesic, does not significantly interact with the CYP3A4 enzyme in a way that would affect the metabolism of atorvastatin to a clinically relevant extent.</li><li>\u2022 Option B. Oxycodone:</li><li>\u2022 Incorrect</li><li>\u2022 opioid analgesic,</li><li>\u2022 does not</li><li>\u2022 CYP3A4 enzyme</li><li>\u2022 metabolism of atorvastatin to a clinically relevant extent.</li><li>\u2022 Option C. Rivaroxaban: Incorrect as rivaroxaban, an anticoagulant , is not metabolized by CYP3A4 in a way that would interfere with atorvastatin metabolism.</li><li>\u2022 Option C. Rivaroxaban:</li><li>\u2022 Incorrect</li><li>\u2022 rivaroxaban,</li><li>\u2022 anticoagulant</li><li>\u2022 not metabolized by CYP3A4</li><li>\u2022 atorvastatin metabolism.</li><li>\u2022 Option D. Adalimumab: Incorrect because adalimumab , an immunosuppressive drug used to treat autoimmune diseases, does not interact with the CYP3A4 enzyme and thus would not affect atorvastatin levels.</li><li>\u2022 Option D. Adalimumab:</li><li>\u2022 Incorrect</li><li>\u2022 adalimumab</li><li>\u2022 immunosuppressive drug</li><li>\u2022 autoimmune diseases, does not</li><li>\u2022 CYP3A4 enzyme</li><li>\u2022 would not</li><li>\u2022 atorvastatin levels.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 When prescribing statins, avoid concomitant use with drugs that inhibit CYP3A4, such as clarithromycin, to prevent an increase in their plasma levels which could lead to myopathy. Other notable CYP3A4 inhibitors to avoid include amiodarone, gemfibrozil, HIV protease inhibitors (such as saquinavir, ritonavir), and itraconazole.</li><li>\u2022 statins,</li><li>\u2022 avoid</li><li>\u2022 inhibit CYP3A4,</li><li>\u2022 clarithromycin,</li><li>\u2022 increase</li><li>\u2022 plasma levels</li><li>\u2022 lead to myopathy.</li><li>\u2022 CYP3A4 inhibitors</li><li>\u2022 amiodarone, gemfibrozil, HIV</li><li>\u2022 protease inhibitors (such as saquinavir, ritonavir), and itraconazole.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c5cc6a89",
      "audio": ""
    },
    {
      "text": "Which of the following statement is True regarding Sacubitril?",
      "options": [
        {
          "label": "A",
          "text": "It is a drug that can act by inhibiting angiotensin converting enzyme",
          "correct": false
        },
        {
          "label": "B",
          "text": "It is a drug used in combination with valsartan for congestive heart failure",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hypokalemia is an adverse effect of sacubitril",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sacubitril is combined with ramipril for treatment of hypertension",
          "correct": false
        }
      ],
      "correct_answer": "B. It is a drug used in combination with valsartan for congestive heart failure",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It is a drug used in combination with valsartan for congestive heart failure</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Incorrect because sacubitril is not an angiotensin converting enzyme (ACE) inhibitor , which typically have names ending in -pril.</li><li>\u2022 Option A.</li><li>\u2022 Incorrect</li><li>\u2022 sacubitril is not an angiotensin converting enzyme (ACE) inhibitor</li><li>\u2022 Option C. Incorrect as hypokalemia is not a side effect associated with sacubitril. It is more commonly associated with traditional diuretics rather than neprilysin inhibitors.</li><li>\u2022 Option C.</li><li>\u2022 Incorrect</li><li>\u2022 hypokalemia</li><li>\u2022 not a side effect</li><li>\u2022 sacubitril.</li><li>\u2022 more</li><li>\u2022 traditional</li><li>\u2022 diuretics</li><li>\u2022 neprilysin inhibitors.</li><li>\u2022 Option D. Incorrect because sacubitril is combined with valsartan, not ramipril , and the combination is used for heart failure, not specifically for hypertension.</li><li>\u2022 Option D.</li><li>\u2022 Incorrect</li><li>\u2022 sacubitril is combined with valsartan, not ramipril</li><li>\u2022 heart failure,</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Sacubitril is a neprilysin inhibitor used in combination with valsartan as an ARNI for the treatment of heart failure to reduce the risk of cardiovascular death and heart failure hospitalization , particularly in patients with reduced ejection fraction.</li><li>\u2022 Sacubitril is a neprilysin inhibitor</li><li>\u2022 with valsartan</li><li>\u2022 ARNI for the treatment of heart failure</li><li>\u2022 reduce the risk</li><li>\u2022 cardiovascular death and heart failure hospitalization</li><li>\u2022 reduced ejection fraction.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cdbbee94",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is an oral renin inhibitor?",
      "options": [
        {
          "label": "A",
          "text": "Candesartan",
          "correct": false
        },
        {
          "label": "B",
          "text": "Aliskiren",
          "correct": true
        },
        {
          "label": "C",
          "text": "Quinapril",
          "correct": false
        },
        {
          "label": "D",
          "text": "Benazepril",
          "correct": false
        }
      ],
      "correct_answer": "B. Aliskiren",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Aliskiren</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Candesartan: Candesartan is an angiotensin II receptor blocker (ARB) . It works by blocking the action of angiotensin II at its receptor, preventing angiotensin II from causing vasoconstriction and aldosterone release, which in turn lowers blood pressure. It does not inhibit renin directly.</li><li>\u2022 Option A. Candesartan:</li><li>\u2022 angiotensin II receptor blocker (ARB)</li><li>\u2022 blocking the action of angiotensin II</li><li>\u2022 preventing angiotensin II</li><li>\u2022 vasoconstriction and aldosterone</li><li>\u2022 lowers blood pressure.</li><li>\u2022 does not inhibit renin</li><li>\u2022 Option C. Quinapril: Quinapril is an angiotensin-converting enzyme (ACE) inhibitor . It inhibits the enzyme responsible for converting angiotensin I to angiotensin II, a potent vasoconstrictor. By reducing the levels of angiotensin II, it lowers blood pressure. Quinapril acts later in the RAAS pathway compared to aliskiren and does not directly inhibit renin.</li><li>\u2022 Option C. Quinapril:</li><li>\u2022 angiotensin-converting enzyme (ACE) inhibitor</li><li>\u2022 converting</li><li>\u2022 angiotensin I to angiotensin II,</li><li>\u2022 potent vasoconstrictor.</li><li>\u2022 reducing</li><li>\u2022 angiotensin II,</li><li>\u2022 lowers blood pressure.</li><li>\u2022 RAAS pathway</li><li>\u2022 to aliskiren</li><li>\u2022 does not directly inhibit renin.</li><li>\u2022 Option D. Benazepril: Benazepril is also an ACE inhibitor, similar to quinapril. It lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, thereby reducing vasoconstriction and aldosterone-mediated volume expansion . Like quinapril, benazepril does not act by inhibiting renin.</li><li>\u2022 Option D. Benazepril:</li><li>\u2022 ACE inhibitor,</li><li>\u2022 quinapril.</li><li>\u2022 lowers blood pressure</li><li>\u2022 inhibiting</li><li>\u2022 conversion of</li><li>\u2022 angiotensin I to angiotensin II,</li><li>\u2022 reducing vasoconstriction</li><li>\u2022 aldosterone-mediated volume expansion</li><li>\u2022 quinapril,</li><li>\u2022 benazepril does not</li><li>\u2022 inhibiting renin.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The objective is to understand the mechanisms of action of various drugs used in the management of hypertension, focusing on their roles within the renin-angiotensin-aldosterone system. Recognizing the unique action of aliskiren as a renin inhibitor, in contrast to ARBs and ACE inhibitors that act downstream, is essential for effective hypertension management.</li><li>\u27a4 mechanisms of action</li><li>\u27a4 management of hypertension,</li><li>\u27a4 renin-angiotensin-aldosterone system.</li><li>\u27a4 aliskiren as a renin inhibitor,</li><li>\u27a4 contrast to ARBs and ACE inhibitors</li><li>\u27a4 act downstream,</li><li>\u27a4 hypertension management.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ec83fcab",
      "audio": ""
    },
    {
      "text": "Which of the following is the drug of choice for digoxin induced ventricular tachyarrhythmias?",
      "options": [
        {
          "label": "A",
          "text": "Quinidine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amiodarone",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lignocaine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Phenytoin",
          "correct": false
        }
      ],
      "correct_answer": "C. Lignocaine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Lignocaine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Quinidine: Quinidine is an antiarrhythmic that can increase serum digoxin levels and is contraindicated in digoxin-induced arrhythmias because it may exacerbate toxicity.</li><li>\u2022 Option A. Quinidine:</li><li>\u2022 antiarrhythmic</li><li>\u2022 increase serum digoxin levels</li><li>\u2022 contraindicated in digoxin-induced arrhythmias</li><li>\u2022 exacerbate toxicity.</li><li>\u2022 Option B. Amiodarone: While amiodarone is a versatile antiarrhythmic agent used in various types of arrhythmias , it can interact with digoxin and increase its levels , potentially worsening toxicity.</li><li>\u2022 Option B. Amiodarone:</li><li>\u2022 versatile antiarrhythmic agent</li><li>\u2022 various types of arrhythmias</li><li>\u2022 interact</li><li>\u2022 digoxin and increase its levels</li><li>\u2022 worsening toxicity.</li><li>\u2022 Option D. Phenytoin: Phenytoin is effective for ventricular arrhythmias, especially in the context of acute myocardial infarction, but it is not the first choice for digoxin-induced arrhythmias. It can be used if lignocaine is not available or contraindicated.</li><li>\u2022 Option D. Phenytoin:</li><li>\u2022 ventricular arrhythmias,</li><li>\u2022 acute myocardial infarction,</li><li>\u2022 not the first choice for digoxin-induced arrhythmias.</li><li>\u2022 can be used</li><li>\u2022 lignocaine is not available or contraindicated.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the appropriate management of digoxin-induced ventricular tachyarrhythmias . Recognizing lignocaine as the drug of choice in this scenario is critical for effectively addressing the cardiac toxicity associated with digoxin overdose , minimizing the risk of further cardiac complications.</li><li>\u27a4 appropriate management of digoxin-induced ventricular tachyarrhythmias</li><li>\u27a4 lignocaine</li><li>\u27a4 drug of choice</li><li>\u27a4 critical for effectively addressing the cardiac toxicity</li><li>\u27a4 digoxin</li><li>\u27a4 overdose</li><li>\u27a4 minimizing the risk</li><li>\u27a4 cardiac complications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3f8d9f12",
      "audio": ""
    },
    {
      "text": "Ivabradine is a drug that has been used in clinical practice for few years now. It is indicated for the management of which of the following diseases?",
      "options": [
        {
          "label": "A",
          "text": "Stable angina",
          "correct": true
        },
        {
          "label": "B",
          "text": "Prerenal azotemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Alzheimer\u2019s disease",
          "correct": false
        },
        {
          "label": "D",
          "text": "Smoking cessation",
          "correct": false
        }
      ],
      "correct_answer": "A. Stable angina",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Stable angina</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Prerenal azotemia: Incorrect as prerenal azotemia is related to kidney function and ivabradine does not have a role in its treatment.</li><li>\u2022 Option B. Prerenal azotemia:</li><li>\u2022 Incorrect</li><li>\u2022 prerenal azotemia</li><li>\u2022 kidney function</li><li>\u2022 ivabradine does not</li><li>\u2022 treatment.</li><li>\u2022 Option C. Alzheimer\u2019s disease: Incorrect because Alzheimer\u2019s disease is a neurodegenerative condition and ivabradine is not indicated for its treatment.</li><li>\u2022 Option C. Alzheimer\u2019s disease:</li><li>\u2022 Incorrect</li><li>\u2022 neurodegenerative condition</li><li>\u2022 ivabradine is not</li><li>\u2022 treatment.</li><li>\u2022 Option D. Smoking cessation: Incorrect as ivabradine is not used in smoking cessation ; it is a cardiac medication used for heart rate control.</li><li>\u2022 Option D. Smoking cessation:</li><li>\u2022 Incorrect</li><li>\u2022 ivabradine</li><li>\u2022 not</li><li>\u2022 smoking cessation</li><li>\u2022 cardiac medication</li><li>\u2022 heart rate</li><li>\u2022 control.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Ivabradine is indicated for the management of stable angina and congestive heart failure . It works by inhibiting the funny current in the SA node , leading to a reduction in heart rate, which is a key therapeutic target in managing these conditions.</li><li>\u2022 Ivabradine</li><li>\u2022 management of stable angina and congestive heart failure</li><li>\u2022 inhibiting the funny current</li><li>\u2022 SA node</li><li>\u2022 reduction in heart rate,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c97323cd",
      "audio": ""
    },
    {
      "text": "Which of the following drug is used in CHF for relief of congestive symptoms and restoration of cardiac performance but does not possess inotropic action?",
      "options": [
        {
          "label": "A",
          "text": "Digoxin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dobutamine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Amrinone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Metoprolol",
          "correct": true
        }
      ],
      "correct_answer": "D. Metoprolol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Metoprolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Digoxin: Digoxin has a positive inotropic effect , increasing the force of cardiac contractions , and is used in CHF to improve symptoms and cardiac performance. It does not fit the criteria as it possesses inotropic action.</li><li>\u2022 Option A. Digoxin:</li><li>\u2022 positive inotropic effect</li><li>\u2022 increasing the force of cardiac contractions</li><li>\u2022 CHF to improve</li><li>\u2022 symptoms and cardiac performance.</li><li>\u2022 does not</li><li>\u2022 inotropic action.</li><li>\u2022 Option B. Dobutamine: Dobutamine is a beta-1 adrenergic agonist with positive inotropic effects , used primarily in acute heart failure to increase cardiac output. It directly increases the force of heart contractions.</li><li>\u2022 Option B. Dobutamine:</li><li>\u2022 beta-1 adrenergic agonist</li><li>\u2022 positive inotropic effects</li><li>\u2022 acute heart</li><li>\u2022 failure</li><li>\u2022 increase cardiac output.</li><li>\u2022 increases the force of heart contractions.</li><li>\u2022 Option C. Amrinone: Amrinone is a phosphodiesterase inhibitor with positive inotropic and vasodilatory effects , used to improve cardiac output in heart failure patients. Like dobutamine and digoxin, it increases the force of cardiac contractions.</li><li>\u2022 Option C. Amrinone:</li><li>\u2022 phosphodiesterase inhibitor</li><li>\u2022 positive inotropic and vasodilatory effects</li><li>\u2022 improve</li><li>\u2022 cardiac output</li><li>\u2022 dobutamine and digoxin,</li><li>\u2022 increases the force of cardiac contractions.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the role of different classes of drugs in the management of CHF, particularly distinguishing those with and without inotropic action. Metoprolol's use in CHF illustrates the importance of managing heart rate and reducing myocardial oxygen demand as part of a strategy to improve cardiac performance without directly increasing the force of contraction</li><li>\u27a4 different classes of drugs</li><li>\u27a4 CHF,</li><li>\u27a4 distinguishing</li><li>\u27a4 with and without inotropic action.</li><li>\u27a4 Metoprolol's</li><li>\u27a4 CHF illustrates</li><li>\u27a4 heart rate and reducing</li><li>\u27a4 myocardial oxygen demand</li><li>\u27a4 improve cardiac performance</li><li>\u27a4 without directly increasing the force of contraction</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5e41d04e",
      "audio": ""
    },
    {
      "text": "Which of the following drug can be used for treatment of euvolemic hyponatremia in patient with advanced congestive heart failure?",
      "options": [
        {
          "label": "A",
          "text": "Tolvaptan",
          "correct": true
        },
        {
          "label": "B",
          "text": "Nesiritide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hydrocortisone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Metoprolol",
          "correct": false
        }
      ],
      "correct_answer": "A. Tolvaptan",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Tolvaptan</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Nesiritide: Incorrect as nesiritide is a recombinant B-type natriuretic peptide used as a b decompensated heart failure, not specifically for euvolemic hyponatremia.</li><li>\u2022 Option B. Nesiritide:</li><li>\u2022 Incorrect</li><li>\u2022 recombinant B-type natriuretic peptide</li><li>\u2022 b</li><li>\u2022 euvolemic hyponatremia.</li><li>\u2022 Option C. Hydrocortisone: Incorrect because hydrocortisone is a corticosteroid and does not address the underlying mechanisms of euvolemic hyponatremia in CHF.</li><li>\u2022 Option C. Hydrocortisone:</li><li>\u2022 Incorrect</li><li>\u2022 hydrocortisone</li><li>\u2022 corticosteroid</li><li>\u2022 does not</li><li>\u2022 euvolemic hyponatremia in CHF.</li><li>\u2022 Option D. Metoprolol: Incorrect as metoprolol is a beta-blocker used in the management of CHF and hypertension , but it is not used to directly treat euvolemic hyponatremia.</li><li>\u2022 Option D. Metoprolol:</li><li>\u2022 Incorrect</li><li>\u2022 metoprolol is a beta-blocker</li><li>\u2022 CHF and hypertension</li><li>\u2022 not used</li><li>\u2022 euvolemic hyponatremia.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 In patients with advanced congestive heart failure presenting with euvolemic hyponatremia, tolvaptan is used to correct water retention and hyponatremia associated with SIADH by antagonizing the vasopressin V2 receptors and increasing water excretion.</li><li>\u2022 advanced congestive heart failure</li><li>\u2022 euvolemic hyponatremia, tolvaptan</li><li>\u2022 correct water</li><li>\u2022 retention and hyponatremia associated with SIADH</li><li>\u2022 antagonizing the vasopressin V2 receptors</li><li>\u2022 increasing water excretion.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ea156058",
      "audio": ""
    },
    {
      "text": "Propranolol can be used in all of the following conditions except.",
      "options": [
        {
          "label": "A",
          "text": "Thyrotoxicosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Variant angina",
          "correct": true
        },
        {
          "label": "C",
          "text": "Migraine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypertension",
          "correct": false
        }
      ],
      "correct_answer": "B. Variant angina",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/88.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Variant angina</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Thyrotoxicosis: Propranolol is used in thyrotoxicosis to provide symptomatic relief from hyperthyroid symptoms such as tachycardia, anxiety, and tremors . It can also inhibit peripheral conversion of T4 to T3.</li><li>\u2022 Option A. Thyrotoxicosis:</li><li>\u2022 Propranolol</li><li>\u2022 thyrotoxicosis</li><li>\u2022 symptomatic relief</li><li>\u2022 hyperthyroid symptoms</li><li>\u2022 tachycardia, anxiety, and tremors</li><li>\u2022 inhibit peripheral conversion of T4 to T3.</li><li>\u2022 Option C. Migraine: Propranolol is used as a prophylactic treatment for migraine . It helps reduce the frequency and severity of migraine attacks.</li><li>\u2022 Option C. Migraine:</li><li>\u2022 Propranolol</li><li>\u2022 prophylactic treatment for migraine</li><li>\u2022 reduce the frequency</li><li>\u2022 severity of</li><li>\u2022 migraine attacks.</li><li>\u2022 Option D. Hypertension: Propranolol can be used in the management of hypertension . It lowers blood pressure by reducing cardiac output and inhibiting renin release from the kidneys.</li><li>\u2022 Option D. Hypertension:</li><li>\u2022 Propranolol</li><li>\u2022 hypertension</li><li>\u2022 lowers blood pressure</li><li>\u2022 reducing cardiac</li><li>\u2022 output</li><li>\u2022 inhibiting</li><li>\u2022 renin</li><li>\u2022 kidneys.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the therapeutic uses and contraindications of propranolol, a non-selective beta-blocke r. Recognizing that propranolol is contraindicated in variant angina due to its potential to worsen coronary artery spasms highlights the importance of considering the specific clinical context when selecting beta-blockers for treatment.</li><li>\u27a4 therapeutic uses</li><li>\u27a4 contraindications of propranolol,</li><li>\u27a4 non-selective beta-blocke</li><li>\u27a4 propranolol is contraindicated in variant angina</li><li>\u27a4 potential to worsen coronary artery spasms</li><li>\u27a4 Indications of \u03b2-Blockers:</li><li>\u27a4 Indications of \u03b2-Blockers:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "28d161c2",
      "audio": ""
    },
    {
      "text": "All the following are adverse effects of amiodarone except:",
      "options": [
        {
          "label": "A",
          "text": "Pulmonary fibrosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Corneal microdeposits",
          "correct": false
        },
        {
          "label": "C",
          "text": "Photosensitivity",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tachycardia",
          "correct": true
        }
      ],
      "correct_answer": "D. Tachycardia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Tachycardia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pulmonary fibrosis: This is a serious and well-recognized side effect of amiodarone, especially with long-term use.</li><li>\u2022 Option A. Pulmonary fibrosis:</li><li>\u2022 serious and well-recognized side effect of amiodarone,</li><li>\u2022 long-term use.</li><li>\u2022 Option B. Corneal microdeposits: Common and typically reversible upon discontinuation of the drug.</li><li>\u2022 Option B. Corneal microdeposits:</li><li>\u2022 Common</li><li>\u2022 reversible upon discontinuation of the drug.</li><li>\u2022 Option C. Photosensitivity: This adverse effect can occur in patients taking amiodarone , leading to increased risk of sunburn and skin pigmentation.</li><li>\u2022 Option C. Photosensitivity:</li><li>\u2022 adverse effect</li><li>\u2022 , leading to increased risk of sunburn and skin</li><li>\u2022 pigmentation.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Amiodarone is a class III anti-arrhythmic drug associated with several adverse effects including pulmonary fibrosis, corneal microdeposits, and photosensitivity, but not tachycardia; in fact, it more commonly causes bradycardia.</li><li>\u2022 Amiodarone</li><li>\u2022 class III anti-arrhythmic drug</li><li>\u2022 several adverse effects</li><li>\u2022 pulmonary fibrosis, corneal</li><li>\u2022 microdeposits, and photosensitivity,</li><li>\u2022 in fact, it more commonly causes bradycardia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d6714317",
      "audio": ""
    },
    {
      "text": "Which of the following is not true about the mechanism of action of digitalis?",
      "options": [
        {
          "label": "A",
          "text": "It binds to the intracellular face of Na + K + ATPase enzyme",
          "correct": true
        },
        {
          "label": "B",
          "text": "There is rise in intracellular Na +",
          "correct": false
        },
        {
          "label": "C",
          "text": "It has positive ionotropic action",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inotropic action of digoxin is independent of cardiac innervation",
          "correct": false
        }
      ],
      "correct_answer": "A. It binds to the intracellular face of Na + K + ATPase enzyme",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) It binds to the intracellular face of Na+ K+ ATPase enzyme.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. There is a rise in intracellular Na+: This statement is true; the inhibition of Na+/K+ ATPase by digitalis leads to increased intracellular sodium.</li><li>\u2022 Option B. There is a rise in intracellular Na+:</li><li>\u2022 true;</li><li>\u2022 inhibition of Na+/K+ ATPase</li><li>\u2022 digitalis</li><li>\u2022 increased</li><li>\u2022 intracellular sodium.</li><li>\u2022 Option C. It has positive inotropic action: This is true; digitalis increases the force of cardiac muscle contraction.</li><li>\u2022 Option</li><li>\u2022 C. It has positive inotropic action:</li><li>\u2022 true;</li><li>\u2022 increases the force of cardiac muscle contraction.</li><li>\u2022 Option D. Inotropic action of digoxin is independent of cardiac innervation: This is also true; digitalis exerts its effects directly on the cardiac muscle cells, not through the nervous system. Though, it can decrease the AV conduction via vagus like action but this action is responsible for its use in atrial fibrillation , not as an inotropic drug.</li><li>\u2022 Option D. Inotropic action of digoxin is independent of cardiac innervation:</li><li>\u2022 true;</li><li>\u2022 cardiac muscle cells, not</li><li>\u2022 nervous system.</li><li>\u2022 can decrease the AV conduction</li><li>\u2022 vagus</li><li>\u2022 use in atrial fibrillation</li><li>\u2022 not as an inotropic drug.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Digitalis binds to the extracellular face of the Na+/K+ ATPase enzyme , leading to increased intracellular calcium, and in turn, positive inotropic action, which enhances cardiac contractility.</li><li>\u2022 Digitalis binds</li><li>\u2022 extracellular face of the Na+/K+ ATPase enzyme</li><li>\u2022 increased intracellular calcium,</li><li>\u2022 positive inotropic action,</li><li>\u2022 cardiac contractility.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "53da824b",
      "audio": ""
    },
    {
      "text": "Fenoldopam is used in the management of?",
      "options": [
        {
          "label": "A",
          "text": "Hypertensive emergencies",
          "correct": true
        },
        {
          "label": "B",
          "text": "Congestive heart failure",
          "correct": false
        },
        {
          "label": "C",
          "text": "Migraine prophylaxis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tachyarrhythmias",
          "correct": false
        }
      ],
      "correct_answer": "A. Hypertensive emergencies",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Hypertensive emergencies</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Congestive heart failure: Fenoldopam is not typically used in the management of congestive heart failure (CHF). Drugs commonly used in CHF include ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists , which work by different mechanisms to reduce the workload on the heart and improve cardiac output .</li><li>\u2022 Option B. Congestive heart failure:</li><li>\u2022 Fenoldopam</li><li>\u2022 not</li><li>\u2022 congestive heart failure (CHF).</li><li>\u2022 CHF include ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists</li><li>\u2022 reduce the workload on the heart</li><li>\u2022 improve cardiac output</li><li>\u2022 Option C. Migraine prophylaxis: Fenoldopam is not used for migraine prophylaxis . Medications for migraine prevention include beta-blockers (such as propranolol), calcium channel blockers, antidepressants, and antiepileptic drugs , which have different mechanisms of action aimed at reducing the frequency and severity of migraine attacks .</li><li>\u2022 Option C. Migraine prophylaxis:</li><li>\u2022 Fenoldopam</li><li>\u2022 not</li><li>\u2022 migraine prophylaxis</li><li>\u2022 beta-blockers (such as propranolol), calcium channel blockers, antidepressants, and antiepileptic drugs</li><li>\u2022 reducing the frequency and severity of migraine attacks</li><li>\u2022 Option D. Tachyarrhythmias: Fenoldopam is not indicated for the treatment of tachyarrhythmias. Drugs used to manage tachyarrhythmias include beta-blockers, calcium channel blockers, antiarrhythmic agents, and sometimes digoxin , depending on the type and cause of the arrhythmia. These medications work by modulating cardiac electrical activity to normalize heart rhythm .</li><li>\u2022 Option D. Tachyarrhythmias:</li><li>\u2022 Fenoldopam</li><li>\u2022 not</li><li>\u2022 tachyarrhythmias. Drugs used</li><li>\u2022 beta-blockers, calcium channel blockers, antiarrhythmic agents, and sometimes digoxin</li><li>\u2022 type and cause of the arrhythmia.</li><li>\u2022 modulating cardiac electrical activity</li><li>\u2022 normalize heart rhythm</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the specific indications for fenoldopam, particularly its role in managing hypertensive emergencies due to its vasodilatory effects and positive impact on renal perfusion . Additionally, recognizing that fenoldopam is not indicated for congestive heart failure, migraine prophylaxis, or tachyarrhythmias underscores the importance of selecting appropriate medications based on the clinical condition being treated.</li><li>\u27a4 specific indications for fenoldopam,</li><li>\u27a4 managing hypertensive emergencies</li><li>\u27a4 its vasodilatory effects</li><li>\u27a4 renal perfusion</li><li>\u27a4 fenoldopam is not</li><li>\u27a4 congestive heart failure, migraine prophylaxis, or tachyarrhythmias</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ccab0f5a",
      "audio": ""
    },
    {
      "text": "A new antiarrhythmic drug is found to be effective against both atrial and ventricular arrhythmias. Its effect on action potential is shown in the Figure. The effect of this new drug is most like:",
      "options": [
        {
          "label": "A",
          "text": "Lignocaine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Propanolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Encainide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Quinidine",
          "correct": true
        }
      ],
      "correct_answer": "D. Quinidine",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/image-2-min.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Quinidine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Lignocaine: Lignocaine (Lidocaine) is a Class IB antiarrhythmic drug that primarily works by shortening the action potential duration by blocking sodium channels , particularly in ischemic or depolarized cells . It does not prolong the action potential plateau.</li><li>\u2022 Option A. Lignocaine:</li><li>\u2022 Class IB antiarrhythmic drug</li><li>\u2022 shortening the action potential</li><li>\u2022 blocking sodium channels</li><li>\u2022 ischemic or depolarized cells</li><li>\u2022 does not</li><li>\u2022 action</li><li>\u2022 potential plateau.</li><li>\u2022 Option B. Propranolol: Propranolol is a Class II antiarrhythmic , which is a beta-blocker that reduces sympathetic nervous system activity. It does not have a direct effect on the action potential duration or plateau phase.</li><li>\u2022 Option B. Propranolol:</li><li>\u2022 Class II antiarrhythmic</li><li>\u2022 beta-blocker</li><li>\u2022 sympathetic nervous system</li><li>\u2022 activity.</li><li>\u2022 does not</li><li>\u2022 action potential duration or plateau phase.</li><li>\u2022 Option C. Encainide: Encainide , which is no longer widely used, was a Class IC antiarrhythmic drug that significantly slows conduction by blocking sodium channels but does not typically prolong the action potential duration.</li><li>\u2022 Option C. Encainide:</li><li>\u2022 Encainide</li><li>\u2022 no longer widely used,</li><li>\u2022 Class IC antiarrhythmic drug</li><li>\u2022 blocking sodium channels</li><li>\u2022 does not</li><li>\u2022 action potential duration.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to recognize the electrophysiologic effects of antiarrhythmic drugs on the cardiac action potential. Understanding how these drugs affect the action potential can provide insights into their therapeutic uses and potential arrhythmogenic risks. Quinidine's effect of prolonging the action potential duration is useful in the treatment of both atrial and ventricular arrhythmias, but it also carries the risk of proarrhythmia, underlining the need for careful patient selection and monitoring.</li><li>\u27a4 electrophysiologic effects of antiarrhythmic drugs</li><li>\u27a4 action potential</li><li>\u27a4 therapeutic uses and potential</li><li>\u27a4 arrhythmogenic risks. Quinidine's</li><li>\u27a4 prolonging the action potential duration</li><li>\u27a4 both atrial and</li><li>\u27a4 ventricular arrhythmias,</li><li>\u27a4 risk of proarrhythmia,</li><li>\u27a4 careful patient selection</li><li>\u27a4 monitoring.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9137afb0",
      "audio": ""
    },
    {
      "text": "A 45-year-old man presents with NYHA Class III breathlessness with a serum creatinine of 2.5 mg/dL and potassium level of 5.5 mEq/L. Which of the following drug is contraindicated?",
      "options": [
        {
          "label": "A",
          "text": "Carvedilol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Spironolactone",
          "correct": true
        },
        {
          "label": "C",
          "text": "Nitroglycerine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Digoxin",
          "correct": false
        }
      ],
      "correct_answer": "B. Spironolactone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Spironolactone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Carvedilol: Incorrect as beta blockers like carvedilol are indicated in CHF and can reduce mortality. They should be started at a very low dose and gradually titrated to the target dose.</li><li>\u2022 Option A. Carvedilol:</li><li>\u2022 Incorrect</li><li>\u2022 carvedilol</li><li>\u2022 indicated in CHF and can reduce mortality.</li><li>\u2022 started</li><li>\u2022 at a very low dose</li><li>\u2022 to</li><li>\u2022 target dose.</li><li>\u2022 Option C. Nitroglycerine: Incorrect because nitroglycerine is a vasodilator that can help reduce the workload of the heart and provide symptomatic relief in CHF.</li><li>\u2022 Option C. Nitroglycerine:</li><li>\u2022 Incorrect</li><li>\u2022 nitroglycerine is a vasodilator</li><li>\u2022 reduce the workload of the heart</li><li>\u2022 symptomatic relief in CHF.</li><li>\u2022 Option D. Digoxin: Incorrect as digoxin is an oral inotropic agent that can be used in chronic CHF to improve symptoms and possibly exercise capacity. Although it is excreted by kidneys but it can be used in renal failure after dose adjustment.</li><li>\u2022 Option D. Digoxin:</li><li>\u2022 Incorrect</li><li>\u2022 oral inotropic agent</li><li>\u2022 chronic CHF</li><li>\u2022 improve</li><li>\u2022 exercise capacity.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 In patients with CHF and compromised renal function or elevated serum potassium levels , potassium-sparing diuretics like spironolactone should b e avoided due to the increased risk of severe hyperkalemia.</li><li>\u2022 CHF and compromised renal function</li><li>\u2022 elevated serum potassium levels</li><li>\u2022 potassium-sparing diuretics</li><li>\u2022 spironolactone</li><li>\u2022 e avoided</li><li>\u2022 increased risk of severe hyperkalemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "df6f9236",
      "audio": ""
    },
    {
      "text": "Trimetazidine is a drug approved for the treatment of angina pectoris. Its mechanism of action is assumed to be:",
      "options": [
        {
          "label": "A",
          "text": "Bradycardiac agent",
          "correct": false
        },
        {
          "label": "B",
          "text": "Rho kinase inhibition",
          "correct": false
        },
        {
          "label": "C",
          "text": "K channel opener",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inhibiting mitochondrial LC3- KAT",
          "correct": true
        }
      ],
      "correct_answer": "D. Inhibiting mitochondrial LC3- KAT",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Inhibiting mitochondrial LC3-KAT</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Incorrect because ivabradine is the bradycardiac agent used for angina , which acts by blocking the funny current in the SA node , not trimetazidine.</li><li>\u2022 Option A.</li><li>\u2022 Incorrect</li><li>\u2022 ivabradine is the bradycardiac agent</li><li>\u2022 for angina</li><li>\u2022 acts by blocking the funny current in the SA</li><li>\u2022 node</li><li>\u2022 Option B. Incorrect as fasudil is the rho kinase inhibitor utilized for angina pectoris , not trimetazidine.</li><li>\u2022 Option B.</li><li>\u2022 Incorrect</li><li>\u2022 fasudil</li><li>\u2022 rho kinase inhibitor utilized for angina pectoris</li><li>\u2022 Option C. Incorrect because nicorandil is the K channel opener (which also has nitric oxide releasing properties ) that is used for angina pectoris, rather than trimetazidine.</li><li>\u2022 Option C.</li><li>\u2022 Incorrect</li><li>\u2022 nicorandil is the K channel opener</li><li>\u2022 nitric oxide releasing properties</li><li>\u2022 used for</li><li>\u2022 angina pectoris,</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Trimetazidine is an antianginal medication that reduces the frequency of angina attacks and increases exercise capacity through a mechanism that likely involves the inhibition of mitochondrial LC3-KAT, leading to a shift from fatty acid to glucose metabolism in the myocardium and resulting in a reduced oxygen demand.</li><li>\u2022 Trimetazidine</li><li>\u2022 antianginal medication</li><li>\u2022 reduces the frequency of angina attacks</li><li>\u2022 increases exercise capacity</li><li>\u2022 inhibition of mitochondrial LC3-KAT,</li><li>\u2022 fatty acid to glucose metabolism</li><li>\u2022 myocardium and resulting</li><li>\u2022 reduced oxygen demand.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "29ec0e37",
      "audio": ""
    },
    {
      "text": "All the following are seen in digitalis toxicity except:",
      "options": [
        {
          "label": "A",
          "text": "Ventricular bigeminy",
          "correct": false
        },
        {
          "label": "B",
          "text": "Paroxysmal atrial tachycardia with fast ventricular rate",
          "correct": true
        },
        {
          "label": "C",
          "text": "Regularization of atrial fibrillation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bidirectional ventricular tachycardia",
          "correct": false
        }
      ],
      "correct_answer": "B. Paroxysmal atrial tachycardia with fast ventricular rate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Paroxysmal atrial tachycardia with fast ventricular rate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Ventricular bigeminy: Seen with digitalis toxicity as it causes increased ventricular ectopy.</li><li>\u2022 Option A. Ventricular bigeminy:</li><li>\u2022 digitalis toxicity</li><li>\u2022 increased ventricular ectopy.</li><li>\u2022 Option C. Regularization of atrial fibrillation: Suggestive of digitalis toxicity where there is an AV block with a regular ventricular rate.</li><li>\u2022 Option C. Regularization of atrial fibrillation:</li><li>\u2022 digitalis toxicity</li><li>\u2022 AV block</li><li>\u2022 regular ventricular</li><li>\u2022 rate.</li><li>\u2022 Option D. Bidirectional ventricular tachycardia: Associated with digitalis toxicity and can manifest in the context of severe structural heart disease.</li><li>\u2022 Option D.</li><li>\u2022 Bidirectional ventricular tachycardia:</li><li>\u2022 digitalis toxicity</li><li>\u2022 severe structural</li><li>\u2022 heart disease.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 In digitalis toxicity, you would expect to see arrhythmias such as ventricular bigeminy, regularization of AF due to AV block, and bidirectional ventricular tachycardia, but not paroxysmal atrial tachycardia with a fast ventricular rate</li><li>\u2022 digitalis toxicity,</li><li>\u2022 arrhythmias such as ventricular bigeminy, regularization of AF due to AV block,</li><li>\u2022 bidirectional ventricular tachycardia,</li><li>\u2022 not paroxysmal atrial tachycardia</li><li>\u2022 fast ventricular rate</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b463740d",
      "audio": ""
    },
    {
      "text": "All are true about starting beta-blocker therapy in a patient with congestive heart failure except:",
      "options": [
        {
          "label": "A",
          "text": "They should be started with optimum doses",
          "correct": true
        },
        {
          "label": "B",
          "text": "They should gradually increase over the weeks",
          "correct": false
        },
        {
          "label": "C",
          "text": "Special precautions should be taken in cases of NYHA class III and IV",
          "correct": false
        },
        {
          "label": "D",
          "text": "Carvedilol and metoprolol are the preferred drugs",
          "correct": false
        }
      ],
      "correct_answer": "A. They should be started with optimum doses",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) They should be started with optimum doses.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Gradually increasing the dose over weeks is correct , as this allows for the patient\u2019s tolerance to the drug to build and minimizes the risk of adverse effects.</li><li>\u2022 Option B. Gradually increasing the dose over weeks</li><li>\u2022 correct</li><li>\u2022 patient\u2019s tolerance to the drug</li><li>\u2022 minimizes</li><li>\u2022 risk of adverse effects.</li><li>\u2022 Option C. Special precautions with NYHA class III and IV patients are necessary due to their increased risk of fluid overload and worsening heart failure.</li><li>\u2022 Option C. Special precautions with NYHA class III and IV patients</li><li>\u2022 increased risk of fluid overload</li><li>\u2022 worsening heart failure.</li><li>\u2022 Option D. Carvedilol and metoprolol are indeed the preferred beta-blockers for treating congestive heart failure due to their proven benefits in this patient population.</li><li>\u2022 Option D. Carvedilol and metoprolol</li><li>\u2022 preferred beta-blockers</li><li>\u2022 congestive heart failure</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 When initiating beta-blocker therapy in congestive heart failure , it is essential to start with very low doses and titrate gradually to minimize risks , especially in patients with more advanced disease (NYHA class III and IV).</li><li>\u2022 beta-blocker</li><li>\u2022 congestive heart failure</li><li>\u2022 start with very low doses and titrate</li><li>\u2022 minimize risks</li><li>\u2022 more advanced disease (NYHA class III and IV).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "88fcbe5e",
      "audio": ""
    },
    {
      "text": "All the following statements about nesiritide are true except?",
      "options": [
        {
          "label": "A",
          "text": "It is a BNP analogue",
          "correct": false
        },
        {
          "label": "B",
          "text": "It can be used in decompensated CHF",
          "correct": false
        },
        {
          "label": "C",
          "text": "It can be administered orally",
          "correct": true
        },
        {
          "label": "D",
          "text": "It causes loss of Na + in the urine",
          "correct": false
        }
      ],
      "correct_answer": "C. It can be administered orally",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) It can be administered orally</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is a BNP analogue: This statement is true. Nesiritide is a synthetic version of BNP that is used in the management of acute decompensated heart failure.</li><li>\u2022 Option A. It is a BNP analogue:</li><li>\u2022 true. Nesiritide</li><li>\u2022 synthetic</li><li>\u2022 BNP</li><li>\u2022 acute decompensated heart failure.</li><li>\u2022 Option B. It can be used in decompensated CHF: This statement is true . Nesiritide is indicated for the treatment of acute decompensated congestive heart failure (CHF), where it works by causing vasodilation and natriuresis.</li><li>\u2022 Option B. It can be used in decompensated CHF:</li><li>\u2022 true</li><li>\u2022 Nesiritide</li><li>\u2022 treatment of acute</li><li>\u2022 decompensated congestive heart failure (CHF),</li><li>\u2022 vasodilation and natriuresis.</li><li>\u2022 Option D. It causes loss of Na+ in the urine: This statement is true . Nesiritide promotes natriuresis, which is the excretion of sodium in the urine , contributing to its beneficial effects in heart failure.</li><li>\u2022 Option D. It causes loss of Na+ in the urine:</li><li>\u2022 true</li><li>\u2022 natriuresis,</li><li>\u2022 excretion of sodium</li><li>\u2022 urine</li><li>\u2022 beneficial effects in heart failure.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the administration and effects of nesiritide in the treatment of acute decompensated heart failure . Nesiritide must be administered intravenously due to its peptide nature and the gastrointestinal degradation of oral peptides</li><li>\u27a4 administration and effects of nesiritide</li><li>\u27a4 acute decompensated heart</li><li>\u27a4 failure</li><li>\u27a4 administered intravenously</li><li>\u27a4 peptide</li><li>\u27a4 gastrointestinal degradation of oral peptides</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ff7e7130",
      "audio": ""
    },
    {
      "text": "Which of the following statements about diazoxide is false?",
      "options": [
        {
          "label": "A",
          "text": "It acts by causing prolonged opening of ATP dependent K + channels in beta cells",
          "correct": false
        },
        {
          "label": "B",
          "text": "It can cause severe hypoglycemia",
          "correct": true
        },
        {
          "label": "C",
          "text": "It can be used to treat patients with insulinoma",
          "correct": false
        },
        {
          "label": "D",
          "text": "It is used as an antihypertensive agent",
          "correct": false
        }
      ],
      "correct_answer": "B. It can cause severe hypoglycemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It can cause severe hypoglycemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. This statement is true as diazoxide does cause prolonged opening of ATP-dependent K+ channels in pancreatic beta cells, leading to decreased insulin release.</li><li>\u2022 Option A.</li><li>\u2022 true as diazoxide</li><li>\u2022 prolonged opening of ATP-dependent K+ channels</li><li>\u2022 decreased insulin release.</li><li>\u2022 Option C. True because diazoxide is used in the treatment of insulinoma due to its ability to suppress insulin secretion .</li><li>\u2022 Option C.</li><li>\u2022 True</li><li>\u2022 diazoxide</li><li>\u2022 insulinoma</li><li>\u2022 ability to suppress insulin secretion</li><li>\u2022 Option D. True since diazoxide has a vasodilatory effect due to its action on potassium channels in blood vessels, making it useful as an antihypertensive agent.</li><li>\u2022 Option D.</li><li>\u2022 True</li><li>\u2022 diazoxide</li><li>\u2022 vasodilatory effect</li><li>\u2022 potassium channels in blood vessels,</li><li>\u2022 antihypertensive agent.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Diazoxide causes hyperglycemia , not hypoglycemia, by i nhibiting insulin release through the opening of K+ channels in pancreatic beta cells and is used in the treatment of insulinoma and as an antihypertensive agent due to its vasodilatory action.</li><li>\u2022 Diazoxide</li><li>\u2022 hyperglycemia</li><li>\u2022 nhibiting insulin release</li><li>\u2022 opening of K+ channels in pancreatic</li><li>\u2022 beta cells</li><li>\u2022 insulinoma</li><li>\u2022 antihypertensive agent</li><li>\u2022 vasodilatory action.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "71f7b012",
      "audio": ""
    },
    {
      "text": "Alpha methyldopa is primarily used for treatment of:",
      "options": [
        {
          "label": "A",
          "text": "Pregnancy induced hypertension",
          "correct": true
        },
        {
          "label": "B",
          "text": "Renovascular hypertension",
          "correct": false
        },
        {
          "label": "C",
          "text": "First line agent in hypertension",
          "correct": false
        },
        {
          "label": "D",
          "text": "Refractory hypertension",
          "correct": false
        }
      ],
      "correct_answer": "A. Pregnancy induced hypertension",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Pregnancy induced hypertension</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Renovascular hypertension: Incorrect as alpha methyldopa is not the first choice of treatment for renovascular hypertension.</li><li>\u2022 Option B. Renovascular hypertension:</li><li>\u2022 Incorrect</li><li>\u2022 alpha methyldopa</li><li>\u2022 not</li><li>\u2022 renovascular</li><li>\u2022 hypertension.</li><li>\u2022 Option C. First line agent in hypertension: Incorrect because alpha methyldopa is not commonly used as a first-line treatment for essential hypertension.</li><li>\u2022 Option C. First line agent in hypertension:</li><li>\u2022 Incorrect</li><li>\u2022 alpha methyldopa</li><li>\u2022 not</li><li>\u2022 first-line treatment for</li><li>\u2022 essential hypertension.</li><li>\u2022 Option D. Refractory hypertension: Incorrect as alpha methyldopa is not typically reserved for refractory hypertension but could be used if other options are unsuitable.</li><li>\u2022 Option D. Refractory hypertension:</li><li>\u2022 Incorrect</li><li>\u2022 alpha methyldopa</li><li>\u2022 not</li><li>\u2022 refractory hypertension</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Alpha methyldopa is mainly used for the treatment of hypertension in pregnancy due to its efficacy and safety profile, acting through central mechanisms by stimulating alpha-2 adrenergic receptors.</li><li>\u2022 Alpha methyldopa</li><li>\u2022 hypertension in pregnancy</li><li>\u2022 efficacy and safety profile,</li><li>\u2022 central mechanisms by stimulating alpha-2 adrenergic receptors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0b06e6d8",
      "audio": ""
    },
    {
      "text": "Which of the following statements about hydralazine is not true?",
      "options": [
        {
          "label": "A",
          "text": "It causes direct relaxation of the blood vessels",
          "correct": false
        },
        {
          "label": "B",
          "text": "It causes dilatation of both arteries and veins",
          "correct": true
        },
        {
          "label": "C",
          "text": "Postural hypotension is not a common problem",
          "correct": false
        },
        {
          "label": "D",
          "text": "It increases plasma renin activity",
          "correct": false
        }
      ],
      "correct_answer": "B. It causes dilatation of both arteries and veins",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It causes dilatation of both arteries and veins</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Correct as hydrala zine does cause direct relaxation of blood vessels, particularly arterioles.</li><li>\u2022 Option A.</li><li>\u2022 Correct</li><li>\u2022 hydrala</li><li>\u2022 direct relaxation of blood vessels,</li><li>\u2022 arterioles.</li><li>\u2022 Option C. Correct because postural hypotension is not a common problem with hydralazine, as it does not significantly dilate veins.</li><li>\u2022 Option C.</li><li>\u2022 Correct</li><li>\u2022 postural hypotension</li><li>\u2022 not a</li><li>\u2022 hydralazine,</li><li>\u2022 does not</li><li>\u2022 dilate veins.</li><li>\u2022 Option D. Correct as vasodilators like hydralazine can cause an increase in plasma renin activity due to compensatory mechanisms following a decrease in blood pressure , such as increased sympathetic activity.</li><li>\u2022 Option D.</li><li>\u2022 Correct as vasodilators like hydralazine</li><li>\u2022 increase in plasma renin activity</li><li>\u2022 compensatory mechanisms</li><li>\u2022 decrease in blood pressure</li><li>\u2022 increased sympathetic activity.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Hydralazine is an antihypertensive agent that predominantly causes arteriolar dilation, resulting in decreased blood pressure without significantly affecting veins or causing postural hypotension.</li><li>\u2022 Hydralazine</li><li>\u2022 antihypertensive agent</li><li>\u2022 arteriolar dilation,</li><li>\u2022 decreased blood pressure</li><li>\u2022 without</li><li>\u2022 veins or causing postural hypotension.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d94a8174",
      "audio": ""
    },
    {
      "text": "All the following statements are true about the use of clonidine in the treatment of hypertension except:",
      "options": [
        {
          "label": "A",
          "text": "It acts by causing a reduction in central sympathetic outflow",
          "correct": false
        },
        {
          "label": "B",
          "text": "It increases LDL-cholesterol on prolonged use",
          "correct": true
        },
        {
          "label": "C",
          "text": "Sedation and xerostomia are common side effects of clonidine",
          "correct": false
        },
        {
          "label": "D",
          "text": "It can be combined with vasodilators",
          "correct": false
        }
      ],
      "correct_answer": "B. It increases LDL-cholesterol on prolonged use",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) It increases LDL-cholesterol on prolonged use</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Correct as clonidine decreases central sympathetic outflow due to its alpha-2 agonist action.</li><li>\u2022 Option A.</li><li>\u2022 Correct</li><li>\u2022 clonidine decreases central sympathetic outflow</li><li>\u2022 alpha-2 agonist action.</li><li>\u2022 Option C. Correct since sedation and xerostomia are well-documented side effects of clonidine.</li><li>\u2022 Option C.</li><li>\u2022 Correct</li><li>\u2022 sedation and xerostomia are well-documented side effects of clonidine.</li><li>\u2022 Option D. Correct because clonidine can be combined with vasodilators to treat hypertension effectively.</li><li>\u2022 Option D.</li><li>\u2022 Correct</li><li>\u2022 clonidine can be combined with vasodilators</li><li>\u2022 hypertension effectively.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Clonidine, an alpha-2 agonist , is used in the treatment of hypertension, primarily by reducing central sympathetic outflow and not by increasing LDL-cholesterol; it actually tends to have a beneficial effect on cholesterol profiles.</li><li>\u2022 Clonidine, an alpha-2 agonist</li><li>\u2022 hypertension,</li><li>\u2022 reducing central sympathetic outflow</li><li>\u2022 not</li><li>\u2022 increasing LDL-cholesterol;</li><li>\u2022 beneficial effect on cholesterol profiles.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a34699a4",
      "audio": ""
    },
    {
      "text": "A patient was taking verapamil for PSVT prophylaxis. He was given propranolol for treatment of essential tremors. This combination can result in:",
      "options": [
        {
          "label": "A",
          "text": "Atrial fibrillation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bradycardia with AV block",
          "correct": true
        },
        {
          "label": "C",
          "text": "Torsades de pointes",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tachycardia",
          "correct": false
        }
      ],
      "correct_answer": "B. Bradycardia with AV block",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Bradycardia with AV block</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Atrial fibrillation is not the most likely outcome of adding verapamil to propranolol therapy, although verapamil is sometimes used to control ventricular rate in patients with atrial fibrillation.</li><li>\u2022 Option A. Atrial fibrillation</li><li>\u2022 not</li><li>\u2022 outcome</li><li>\u2022 verapamil to propranolol</li><li>\u2022 verapamil is</li><li>\u2022 to control ventricular rate</li><li>\u2022 atrial fibrillation.</li><li>\u2022 Option C. Torsades\u2019 de pointes is a specific type of ventricular tachycardia often associated with a prolonged QT interval , which is not a typical side effect of either propranolol or verapamil.</li><li>\u2022 Option C. Torsades\u2019</li><li>\u2022 specific type of ventricular tachycardia</li><li>\u2022 prolonged QT interval</li><li>\u2022 not a typical side effect</li><li>\u2022 propranolol or verapamil.</li><li>\u2022 Option D. Tachycardia , or increased heart rate , would be unlikely as both drug s work to slow the heart rate.</li><li>\u2022 Option D. Tachycardia</li><li>\u2022 increased heart rate</li><li>\u2022 unlikely as both drug</li><li>\u2022 slow the heart rate.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objectives:</li><li>\u27a4 Therefore, the most appropriate answer in the context of this clinical scenario is B. Bradycardia with AV block, considering the pharmacological actions of both propranolol and verapamil and the symptoms reported by the patient.</li><li>\u27a4 B. Bradycardia</li><li>\u27a4 AV block,</li><li>\u27a4 pharmacological actions of both propranolol and verapamil</li><li>\u27a4 symptoms</li><li>\u27a4 Ref: KDT 8th/160</li><li>\u27a4 Ref: KDT 8th/160</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8d396a86",
      "audio": ""
    },
    {
      "text": "Sodium nitroprusside acts by stimulation of?",
      "options": [
        {
          "label": "A",
          "text": "Guanylyl cyclase",
          "correct": true
        },
        {
          "label": "B",
          "text": "Phosphokinase 1,2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Phospholipase A",
          "correct": false
        },
        {
          "label": "D",
          "text": "Phospholipase B",
          "correct": false
        }
      ],
      "correct_answer": "A. Guanylyl cyclase",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Guanylyl cyclase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Phosphokinase 1,2: There is no enzyme specifically named phosphokinase 1,2. This option does not relate to the known mechanism of action of sodium nitroprusside.</li><li>\u2022 Option B. Phosphokinase 1,2:</li><li>\u2022 no</li><li>\u2022 phosphokinase 1,2.</li><li>\u2022 does not</li><li>\u2022 Option C. Phospholipase A: Phospholipase A is an enzyme that hydrolyzes phospholipids to produce fatty acids and lysophospholipids . It is not directly involved in the mechanism of action of sodium nitroprusside.</li><li>\u2022 Option C. Phospholipase A:</li><li>\u2022 Phospholipase A is an enzyme</li><li>\u2022 hydrolyzes phospholipids</li><li>\u2022 fatty acids</li><li>\u2022 lysophospholipids</li><li>\u2022 not</li><li>\u2022 mechanism of action of sodium nitroprusside.</li><li>\u2022 Option D. Phospholipase B: Phospholipase B also acts on phospholipids but is not related to the vasodilatory action of sodium nitroprusside.</li><li>\u2022 Option D. Phospholipase B:</li><li>\u2022 acts on phospholipids</li><li>\u2022 not</li><li>\u2022 vasodilatory action of sodium</li><li>\u2022 nitroprusside.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the pharmacodynamics of sodium nitroprusside , a potent vasodilator. By knowing that its mechanism involves th e stimulation of guanylyl cyclase and the subsequent increase in cGMP, healthcare professionals can better anticipate its effects and necessary precautions, such as monitoring for signs of cyanide toxicity due to its metabolism. Understanding the differences in mechanisms among various vasodilators is crucial for selecting the appropriate agent in clinical scenarios.</li><li>\u27a4 pharmacodynamics of sodium nitroprusside</li><li>\u27a4 potent vasodilator.</li><li>\u27a4 e stimulation of guanylyl cyclase</li><li>\u27a4 increase in cGMP,</li><li>\u27a4 monitoring for signs of cyanide toxicity</li><li>\u27a4 differences in mechanisms</li><li>\u27a4 vasodilators</li><li>\u27a4 selecting the appropriate agent</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "95f8841e",
      "audio": ""
    },
    {
      "text": "A 72-year-old woman with a history of ischemic cardiomyopathy and left ventricular ejection fraction of 35%. She is NYHA class II in terms of symptoms. She is on lisinopril, carvedilol, and spironolactone. Her blood pressure is 102/82 mmHg, and heart rate is 80 bpm. Which of the following additional medications will further reduce her risk of hospitalization due to heart failure?",
      "options": [
        {
          "label": "A",
          "text": "Aliskiren",
          "correct": false
        },
        {
          "label": "B",
          "text": "Digoxin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ivabradine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Valsartan",
          "correct": false
        }
      ],
      "correct_answer": "C. Ivabradine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Ivabradine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Aliskiren: Aliskiren is a direct renin inhibitor and is used to treat hypertension. While it can reduce blood pressure and has been studied in heart failure , it is not specifically indicated to reduce mortality in heart failure patients , particularly when already on optimal therapy with an ACE inhibitor, beta-blocker, and aldosterone antagonist.</li><li>\u2022 Option A. Aliskiren:</li><li>\u2022 direct renin inhibitor</li><li>\u2022 hypertension.</li><li>\u2022 reduce blood pressure</li><li>\u2022 heart failure</li><li>\u2022 not</li><li>\u2022 reduce mortality in heart failure patients</li><li>\u2022 ACE inhibitor, beta-blocker, and aldosterone antagonist.</li><li>\u2022 Option B. Digoxin: Digoxin may help improve symptoms and reduce hospitalizations by increasing contractility and controlling heart rate, but it has not been shown to reduce mortality in heart failure patients.</li><li>\u2022 Option B. Digoxin:</li><li>\u2022 improve</li><li>\u2022 reduce hospitalizations</li><li>\u2022 increasing contractility and controlling heart rate,</li><li>\u2022 has not</li><li>\u2022 reduce mortality in heart failure patients.</li><li>\u2022 Option D. Valsartan: The patient is already on lisinopril, an ACE inhibitor, which provides the mortality benefit of inhibiting the renin-angiotensin-aldosterone system (RAAS). Adding another RAAS inhibitor like valsartan, an ARB, without removing the ACE inhibitor is not typically recommended due to increased risk of adverse effects without additional mortality benefit.</li><li>\u2022 Option D. Valsartan:</li><li>\u2022 lisinopril, an ACE inhibitor,</li><li>\u2022 mortality benefit of inhibiting the renin-angiotensin-aldosterone system (RAAS).</li><li>\u2022 valsartan, an ARB, without removing the ACE inhibitor</li><li>\u2022 not</li><li>\u2022 increased risk of adverse effects without additional mortality benefit.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ivabradine can be used in certain heart failure patients with a high heart rate despite optimal standard therapy to further reduce the risk of heart failure-related morbidity. It is important to recognize the therapeutic benefits and limitations of additional heart failure treatments in the context of a patient's overall medical regimen and clinical status.</li><li>\u27a4 Ivabradine</li><li>\u27a4 certain heart failure</li><li>\u27a4 high heart rate</li><li>\u27a4 reduce the risk of heart failure-related morbidity.</li><li>\u27a4 recognize the therapeutic benefits</li><li>\u27a4 limitations of</li><li>\u27a4 additional heart failure</li><li>\u27a4 Ref : CMDT 2022 Pg 410</li><li>\u27a4 Ref : CMDT 2022 Pg 410</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "506902d1",
      "audio": ""
    },
    {
      "text": "Which of the following medications has been shown to reduce mortality in heart failure with reduced ejection fraction?",
      "options": [
        {
          "label": "A",
          "text": "Digoxin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Furosemide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Metoprolol succinate",
          "correct": true
        },
        {
          "label": "D",
          "text": "Dobutamine",
          "correct": false
        }
      ],
      "correct_answer": "C. Metoprolol succinate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Metoprolol succinate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Digoxin: While digoxin can improve symptoms and reduce hospitalizations by increasing the force of cardiac c ontractions and controlling heart rate in patients with heart failure, it has not been shown to reduce mortality in these patients.</li><li>\u2022 Option A. Digoxin:</li><li>\u2022 improve symptoms and reduce hospitalizations by increasing the force of cardiac c</li><li>\u2022 controlling heart rate</li><li>\u2022 heart failure,</li><li>\u2022 has not been shown to reduce mortality</li><li>\u2022 Option B. Furosemide: Furosemide is a loop diuretic that is used to reduce symptoms of congestion in heart failure by promoting the excretion of sodium and water . However, it does not have a direct effect on reducing mortality in heart failure with reduced ejection fraction.</li><li>\u2022 Option B. Furosemide:</li><li>\u2022 loop diuretic</li><li>\u2022 reduce symptoms of congestion in heart failure</li><li>\u2022 excretion of sodium and water</li><li>\u2022 does not</li><li>\u2022 direct effect on reducing mortality in heart failure</li><li>\u2022 reduced</li><li>\u2022 ejection fraction.</li><li>\u2022 Option D. Dobutamine: Dobutamine is a beta-1 agonist used in acute heart failure to increase cardiac output . It is generally used for short-term support in hospitalized patients and is not shown to reduce long-term mortality in chronic heart failure ; its long-term use can actually be harmful due to increased cardiac oxygen demand and potential for arrhythmia.</li><li>\u2022 Option D. Dobutamine:</li><li>\u2022 beta-1 agonist</li><li>\u2022 acute heart failure to increase cardiac output</li><li>\u2022 short-term support in hospitalized patients</li><li>\u2022 not</li><li>\u2022 reduce long-term mortality in chronic heart failure</li><li>\u2022 harmful due to increased cardiac oxygen demand</li><li>\u2022 arrhythmia.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the role of different classes of drugs in the treatment of heart failure with reduced ejection fraction, particularly those that have been demonstrated to reduce mortality.</li><li>\u27a4 different classes of drugs</li><li>\u27a4 heart failure</li><li>\u27a4 reduced ejection</li><li>\u27a4 fraction,</li><li>\u27a4 have been demonstrated to reduce mortality.</li><li>\u27a4 Drugs reducing mortality in CHF include:</li><li>\u27a4 Drugs reducing mortality in CHF include:</li><li>\u27a4 Beta blockers ACE inhibitors ARBs Aldosterone antagonists Ivabradine Hydralazine + Isosorbide dinitrate</li><li>\u27a4 Beta blockers</li><li>\u27a4 ACE inhibitors</li><li>\u27a4 ARBs</li><li>\u27a4 Aldosterone antagonists</li><li>\u27a4 Ivabradine</li><li>\u27a4 Hydralazine + Isosorbide dinitrate</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "36c34edb",
      "audio": ""
    },
    {
      "text": "The primary mechanism of action of nitrates in a patient of classical angina is:",
      "options": [
        {
          "label": "A",
          "text": "Coronary vasodilation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decrease heart rate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Decreased afterload",
          "correct": false
        },
        {
          "label": "D",
          "text": "Decreases preload",
          "correct": true
        }
      ],
      "correct_answer": "D. Decreases preload",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Decreases preload</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Coronary Vasodilation : Nitrates do cause some coronary vasodilation, but this is not their primary action in treating classical angina. Endothelium independent coronary vasodilation is the primary mechanism of nitrates in treatment of variant angina. In a typical vascular system, the endothelium plays a crucial role in regulating blood vessel tone and blood flow . It does this by releasing substances like nitric oxide (NO), which promote vasodilation. However, nitrates work independently of the endothelial cells. They are converted into nitric oxide (NO) within the smooth muscle cells. This NO then activates an enzyme called guanylate cyclase , which increases the levels of cyclic guanosine monophosphate (cGMP). The increase in cGMP leads to relaxation of the smooth muscle cells , resulting in vasodilatio n. This mechanism is particularly important in conditions like variant angina, where there are episodes of coronary artery spasm . Nitrate s can effectively relax the smooth muscle in the coronary arteries, reducing the spasm and thus alleviating the angina pain . This action is independent of the endothelium, which may not be functioning optimally in all individuals with coronary artery disease.</li><li>\u2022 Option A. Coronary Vasodilation</li><li>\u2022 Nitrates do</li><li>\u2022 coronary vasodilation,</li><li>\u2022 not their primary action</li><li>\u2022 classical angina.</li><li>\u2022 Endothelium independent coronary vasodilation</li><li>\u2022 primary</li><li>\u2022 nitrates</li><li>\u2022 variant</li><li>\u2022 angina.</li><li>\u2022 endothelium</li><li>\u2022 regulating blood vessel tone and blood flow</li><li>\u2022 nitric oxide (NO),</li><li>\u2022 promote vasodilation.</li><li>\u2022 nitrates work independently of the endothelial</li><li>\u2022 cells.</li><li>\u2022 converted into nitric oxide (NO)</li><li>\u2022 within</li><li>\u2022 smooth muscle cells.</li><li>\u2022 NO</li><li>\u2022 guanylate cyclase</li><li>\u2022 increases the levels of cyclic guanosine monophosphate (cGMP).</li><li>\u2022 increase in cGMP</li><li>\u2022 smooth muscle cells</li><li>\u2022 vasodilatio</li><li>\u2022 variant angina,</li><li>\u2022 episodes of coronary artery spasm</li><li>\u2022 Nitrate</li><li>\u2022 relax the smooth muscle</li><li>\u2022 coronary arteries,</li><li>\u2022 reducing the spasm</li><li>\u2022 alleviating the angina pain</li><li>\u2022 independent</li><li>\u2022 endothelium,</li><li>\u2022 not</li><li>\u2022 functioning optimally</li><li>\u2022 coronary artery disease.</li><li>\u2022 Option B. Decrease Heart Rate : Nitrates do not have a significant effect on heart rate. Drugs that primarily decrease heart rate , such as beta-blockers , are used separately for this purpose in the management of angina.</li><li>\u2022 Option B. Decrease Heart Rate</li><li>\u2022 do not</li><li>\u2022 heart rate.</li><li>\u2022 primarily decrease heart rate</li><li>\u2022 beta-blockers</li><li>\u2022 Option C. Decrease Afterload : While nitrates can have a minor effect on afterload due to systemic vasodilation , decreasing afterload is not their primary mechanism of action in treating angina . Medications like ACE inhibitors or angiotensin receptor blockers are more effective for this purpose.</li><li>\u2022 Option C. Decrease Afterload</li><li>\u2022 nitrates</li><li>\u2022 minor effect on afterload</li><li>\u2022 systemic vasodilation</li><li>\u2022 decreasing</li><li>\u2022 afterload</li><li>\u2022 not</li><li>\u2022 treating angina</li><li>\u2022 ACE inhibitors or angiotensin receptor</li><li>\u2022 blockers</li><li>\u2022 more</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The mechanism of action of nitrates in classical angina is decrease in preload. The mechanism of action of nitrates i n variant angina is endothelium independent coronary vasodilation.</li><li>\u2022 The mechanism of action of nitrates in classical angina is decrease in preload.</li><li>\u2022 mechanism of action of nitrates</li><li>\u2022 classical angina is decrease in preload.</li><li>\u2022 The mechanism of action of nitrates i n variant angina is endothelium independent coronary vasodilation.</li><li>\u2022 mechanism of action of nitrates</li><li>\u2022 n variant angina</li><li>\u2022 endothelium independent coronary vasodilation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f27f6d3d",
      "audio": ""
    },
    {
      "text": "A 56-year-old patient with essential hypertension on ACE inhibitors for 6 months developed chronic refractory dry cough. What would be the correct action to be taken?",
      "options": [
        {
          "label": "A",
          "text": "Reduce the dose of ACE inhibitor",
          "correct": false
        },
        {
          "label": "B",
          "text": "Add anti- tussive for treatment of cough",
          "correct": false
        },
        {
          "label": "C",
          "text": "Change to Angiotensin receptor blocker (ARB)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Order for a CT scan of chest",
          "correct": false
        }
      ],
      "correct_answer": "C. Change to Angiotensin receptor blocker (ARB)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Change to Angiotensin receptor blocker (ARB)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Reduce the dose of ACE inhibitor: Reducing the dose of the ACE inhibitor would not alleviate the cough since the adverse effect is not dose-related and the patient has already developed sensitivity to the drug.</li><li>\u2022 Option A. Reduce the dose of ACE inhibitor:</li><li>\u2022 would not alleviate the cough</li><li>\u2022 Option B. Add anti-tussive for the treatment of cough: An anti-tussive would not address the underlying cause of the cough, which in this case is due to the ACE inhibitors.</li><li>\u2022 Option B. Add anti-tussive for the treatment of cough:</li><li>\u2022 would not</li><li>\u2022 cause of the cough,</li><li>\u2022 due to the ACE inhibitors.</li><li>\u2022 Option D. Order for a CT scan of the chest: A CT scan would be an unnecessary investigation and an additional cost burden for the patient, given that the cause of the chronic cough is already known to be drug-related and not indicative of an underlying pulmonary pathology.</li><li>\u2022 Option D. Order for a CT scan of the chest:</li><li>\u2022 unnecessary investigation</li><li>\u2022 chronic cough is already known to be drug-related</li><li>\u2022 not indicative of an underlying</li><li>\u2022 pulmonary pathology.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 For a patient who develops a chronic dry cough while on ACE inhibitors, changing to an Angiotensin receptor blocker (ARB) is the correct course of action, a s ARBs do not cause this side effect.</li><li>\u2022 chronic dry cough while on ACE inhibitors,</li><li>\u2022 Angiotensin receptor blocker (ARB)</li><li>\u2022 correct course of action,</li><li>\u2022 s ARBs do not</li><li>\u2022 side effect.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e2b282a8",
      "audio": ""
    },
    {
      "text": "Which of the following drugs can result in prolongation of QT interval in ECG?",
      "options": [
        {
          "label": "A",
          "text": "Quinidine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Lignocaine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ciprofloxacin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Propranolol",
          "correct": false
        }
      ],
      "correct_answer": "A. Quinidine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-113043.png"
      ],
      "explanation": "<p><strong>Ans. A) Quinidine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Lignocaine: Lignocaine (also known as lidocaine) is a class Ib anti-arrhythmic drug that predominantly blocks Na+ channels and is less likely to cause QT prolongation as its action is more specific to the fast sodium channels and it actually tends to shorten the action potential duration.</li><li>\u2022 Option B. Lignocaine:</li><li>\u2022 class Ib anti-arrhythmic drug</li><li>\u2022 blocks Na+ channels</li><li>\u2022 less</li><li>\u2022 QT prolongation</li><li>\u2022 more specific to the fast sodium channels</li><li>\u2022 shorten the action potential duration.</li><li>\u2022 Option C. Ciprofloxacin: Ciprofloxacin is a fluoroquinolone antibiotic . Although fluoroquinolones like sparfloxacin, levofloxacin, and moxifloxacin are associated with QT prolongation, ciprofloxacin is less implicated in causing this adverse effect when compared to other drugs in its class.</li><li>\u2022 Option C. Ciprofloxacin:</li><li>\u2022 fluoroquinolone antibiotic</li><li>\u2022 sparfloxacin, levofloxacin, and</li><li>\u2022 moxifloxacin</li><li>\u2022 QT prolongation, ciprofloxacin is less</li><li>\u2022 adverse effect</li><li>\u2022 Option D. Propranolol: Propranolol is a non-selective beta-blocker and is not commonly associated with QT prolongation . It acts on the beta-adrenergic receptors and can affect heart rate and contractility but not typically the QT interval.</li><li>\u2022 Option D. Propranolol:</li><li>\u2022 non-selective beta-blocker</li><li>\u2022 not</li><li>\u2022 QT prolongation</li><li>\u2022 beta-adrenergic receptors</li><li>\u2022 heart rate and contractility</li><li>\u2022 not</li><li>\u2022 QT interval.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Quinidine, a class Ia anti-arrhythmic drug , can cause QT interval prolongation on an ECG due to its blockade of potassium channels, which affects the repolarization phase of the cardiac action potential.</li><li>\u2022 Quinidine,</li><li>\u2022 class Ia anti-arrhythmic drug</li><li>\u2022 QT interval prolongation on an ECG</li><li>\u2022 blockade of potassium channels,</li><li>\u2022 repolarization phase of the cardiac action potential.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b2536843",
      "audio": ""
    },
    {
      "text": "Preferred drug for the treatment of uncomplicated grade 2 hypertension in a 48-year-old man is?",
      "options": [
        {
          "label": "A",
          "text": "Chlorthalidone",
          "correct": true
        },
        {
          "label": "B",
          "text": "Triamterene",
          "correct": false
        },
        {
          "label": "C",
          "text": "Spironolactone",
          "correct": false
        },
        {
          "label": "D",
          "text": "Furosemide",
          "correct": false
        }
      ],
      "correct_answer": "A. Chlorthalidone",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-114419.png"
      ],
      "explanation": "<p><strong>Ans. A) Chlorthalidone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Triamterene: Triamterene is a potassium-sparing diuretic that is not typically used as first-line treatment for hypertension. It is often used in combination with other diuretics to prevent hypokalemia.</li><li>\u2022 Option B. Triamterene:</li><li>\u2022 potassium-sparing diuretic</li><li>\u2022 not</li><li>\u2022 first-line treatment for hypertension.</li><li>\u2022 used in combination</li><li>\u2022 diuretics to prevent hypokalemia.</li><li>\u2022 Option C. Spironolactone: Spironolactone is another potassium-sparing diuretic that also blocks the effects of aldosterone . While it can be used for hypertension , it is usually reserved for cases that are resistant to other treatments or for specific conditions like primary hyperaldosteronism.</li><li>\u2022 Option C. Spironolactone:</li><li>\u2022 potassium-sparing diuretic</li><li>\u2022 blocks the effects of aldosterone</li><li>\u2022 hypertension</li><li>\u2022 resistant to other treatments</li><li>\u2022 specific conditions like</li><li>\u2022 primary hyperaldosteronism.</li><li>\u2022 Option D. Furosemide: Furosemide is a loop diuretic that is primarily used for the treatment of edema associated with heart failure or renal disease. It is not typically used as first-line treatment for uncomplicated hypertension due to its shorter duration of action and greater risk for electrolyte imbalances.</li><li>\u2022 Option D. Furosemide:</li><li>\u2022 loop diuretic</li><li>\u2022 edema associated with heart failure</li><li>\u2022 renal disease.</li><li>\u2022 not</li><li>\u2022 first-line treatment for uncomplicated hypertension</li><li>\u2022 shorter duration of action and</li><li>\u2022 electrolyte imbalances.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to identify the preferred initial treatment options for hypertension. Thiazide-like diuretics such as chlorthalidone are recommended as first-line therapy for most patients with hypertension due to their effectiveness in lowering blood pressure and reducing the risk of cardiovascular events.</li><li>\u27a4 initial treatment</li><li>\u27a4 hypertension.</li><li>\u27a4 chlorthalidone are recommended as first-line therapy</li><li>\u27a4 hypertension</li><li>\u27a4 lowering</li><li>\u27a4 blood pressure and reducing the risk of cardiovascular events.</li><li>\u27a4 FIRST LINE DRUGS FOR DIFFERENT PATIENTS WITH HYPERTENSION</li><li>\u27a4 FIRST LINE DRUGS FOR DIFFERENT PATIENTS WITH HYPERTENSION</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "50383bc7",
      "audio": ""
    },
    {
      "text": "Nitrates are an important group of vasodilators used for angina and hypertension. These drugs primarily act by:",
      "options": [
        {
          "label": "A",
          "text": "Activation of guanylyl cyclase and decrease in cGMP",
          "correct": false
        },
        {
          "label": "B",
          "text": "Activation of guanylyl cyclase and increase in cGMP",
          "correct": true
        },
        {
          "label": "C",
          "text": "Activation of guanylyl cyclase and decrease in cAMP",
          "correct": false
        },
        {
          "label": "D",
          "text": "Activation of guanylyl cyclase and increase in cAMP",
          "correct": false
        }
      ],
      "correct_answer": "B. Activation of guanylyl cyclase and increase in cGMP",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Activation of guanylyl cyclase and increase in cGMP</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the mechanism of action of nitrates in the treatment of angina and hypertension. Knowledge that nitrates increase cGMP levels through the activation of guanylyl cyclase is fundamental in understanding how these drugs induce vasodilation and relieve symptoms associated with ischemic heart disease . This mechanism is also the basis for the use of nitrates in other conditions where vasodilation is beneficial.</li><li>\u27a4 mechanism of action of nitrates</li><li>\u27a4 angina and hypertension.</li><li>\u27a4 nitrates increase cGMP levels</li><li>\u27a4 activation of guanylyl cyclase</li><li>\u27a4 vasodilation</li><li>\u27a4 relieve symptoms associated with ischemic heart disease</li><li>\u27a4 use of</li><li>\u27a4 nitrates</li><li>\u27a4 vasodilation is beneficial.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d7cbb107",
      "audio": ""
    },
    {
      "text": "Why does adenosine have a short half-life?",
      "options": [
        {
          "label": "A",
          "text": "Spontaneous hydrolysis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Rapid metabolism by enzymes in the liver",
          "correct": false
        },
        {
          "label": "C",
          "text": "Uptake in RBC and endothelial cells",
          "correct": true
        },
        {
          "label": "D",
          "text": "Renal excretion",
          "correct": false
        }
      ],
      "correct_answer": "C. Uptake in RBC and endothelial cells",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Uptake in RBC and endothelial cells</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Spontaneous hydrolysis: While spontaneous hydrolysis can occur, it is not the primary reason for adenosine's short half-life in vivo.</li><li>\u2022 Option A. Spontaneous hydrolysis:</li><li>\u2022 Option B. Rapid metabolism by enzymes in the liver: Although liver enzymes play a role in drug metabolism, in the case of adenosine, the rapid uptake and metabolism by RBCs and endothelial cells are more significant.</li><li>\u2022 Option B. Rapid metabolism by enzymes in the liver:</li><li>\u2022 Option D. Renal excretion: While renal excretion does remove substances from the blood, adenosine's short half-life is due more to cellular uptake and metabolism than to excretion by the kidneys.</li><li>\u2022 Option D. Renal excretion:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Adenosine has a short half-life due to rapid uptake and intracellular metabolism in RBCs and endothelial cells, where it is phosphorylated to AMP or deaminated to eventually form uric acid. Adenosine is also the drug of choice (DOC) for the treatment of paroxysmal supraventricular tachycardia (PSVT).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4def609a",
      "audio": ""
    },
    {
      "text": "Which of the following drugs act as K channel opener?",
      "options": [
        {
          "label": "A",
          "text": "Spironolactone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amiloride",
          "correct": false
        },
        {
          "label": "C",
          "text": "Nicorandil",
          "correct": true
        },
        {
          "label": "D",
          "text": "Methyldopa",
          "correct": false
        }
      ],
      "correct_answer": "C. Nicorandil",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Nicorandil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Spironolactone: Spironolactone is a potassium-sparing diuretic that works at the level of the distal convoluted tubule in the kidneys but does not act as a K channel opener in the cardiovascular system.</li><li>\u2022 Option A. Spironolactone:</li><li>\u2022 potassium-sparing diuretic</li><li>\u2022 at the level of the distal convoluted tubule</li><li>\u2022 does not act</li><li>\u2022 K channel opener</li><li>\u2022 Option B. Amiloride: Amiloride is also a potassium-sparing diuretic that affects ion channels in the kidneys , but again, it does not open potassium channels in vascular smooth muscle.</li><li>\u2022 Option B. Amiloride:</li><li>\u2022 potassium-sparing diuretic</li><li>\u2022 ion channels in the kidneys</li><li>\u2022 does not</li><li>\u2022 open potassium channels</li><li>\u2022 Option D. Methyldopa: Methyldopa is an antihypertensive medication that acts centrally as an alpha-2 agonist to lower blood pressure . It does not have K channel opening properties.</li><li>\u2022 Option D. Methyldopa:</li><li>\u2022 antihypertensive medication</li><li>\u2022 acts centrally as an alpha-2 agonist</li><li>\u2022 lower blood</li><li>\u2022 pressure</li><li>\u2022 does not</li><li>\u2022 K channel opening properties.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Nicorandil acts as a K channel opener and has nitrate-like properties, making it effective in the treatment of angina pectoris due to its ability to reduce myocardial oxygen demand and increase blood flow to the ischemic heart muscle.</li><li>\u27a4 Nicorandil</li><li>\u27a4 K channel opener and has nitrate-like properties,</li><li>\u27a4 treatment of angina pectoris</li><li>\u27a4 reduce myocardial oxygen demand</li><li>\u27a4 increase blood flow to the ischemic heart muscle.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "da88427b",
      "audio": ""
    },
    {
      "text": "A 35-year-old female treated with an antihypertensive drug and presented with the following features shown in figure. Likely agent is?",
      "options": [
        {
          "label": "A",
          "text": "Methyl Dopa",
          "correct": false
        },
        {
          "label": "B",
          "text": "Minoxidil",
          "correct": true
        },
        {
          "label": "C",
          "text": "Captopril",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fenoldopam",
          "correct": false
        }
      ],
      "correct_answer": "B. Minoxidil",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/41.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Minoxidil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Methyldopa: Methyldopa is an antihypertensive medication that can cause side effects such as drowsiness and dry mouth but is not commonly associated with hirsutism.</li><li>\u2022 Option A. Methyldopa:</li><li>\u2022 antihypertensive medication</li><li>\u2022 drowsiness and dry mouth</li><li>\u2022 Option C. Captopril: Captopril is an ACE inhibitor used to treat high blood pressure and heart failure . It can cause a persistent dry cough, taste changes, and in rare cases, angioedema, but not hirsutism.</li><li>\u2022 Option C. Captopril:</li><li>\u2022 ACE inhibitor</li><li>\u2022 high blood pressure and heart failure</li><li>\u2022 dry</li><li>\u2022 cough, taste changes,</li><li>\u2022 angioedema,</li><li>\u2022 Option D. Fenoldopam: Fenoldopam is a vasodilator used in hypertensive emergen cies, acting as a dopamine D1 receptor agonist . It does not have hirsutism listed as a side effect.</li><li>\u2022 Option D. Fenoldopam:</li><li>\u2022 vasodilator</li><li>\u2022 hypertensive emergen</li><li>\u2022 dopamine D1 receptor agonist</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to recognize the important drugs causing hirsutism. These include:</li><li>\u27a4 important drugs</li><li>\u27a4 hirsutism.</li><li>\u27a4 Minoxidil Cyclosporine Phenytoin Androgens</li><li>\u27a4 Minoxidil</li><li>\u27a4 Minoxidil</li><li>\u27a4 Cyclosporine</li><li>\u27a4 Cyclosporine</li><li>\u27a4 Phenytoin</li><li>\u27a4 Phenytoin</li><li>\u27a4 Androgens</li><li>\u27a4 Androgens</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f22bec76",
      "audio": ""
    },
    {
      "text": "A 55 yr. old male presented to emergency with severe acute chest pain, radiating to left shoulder and back in the last 20 minutes. It was associated with sweating. ECG is shown in the figure. Which of the following drug should be given to the patient?",
      "options": [
        {
          "label": "A",
          "text": "Amiodarone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Adenosine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tenecteplase",
          "correct": true
        },
        {
          "label": "D",
          "text": "Verapamil",
          "correct": false
        }
      ],
      "correct_answer": "C. Tenecteplase",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/42.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Tenecteplase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Amiodarone: Amiodarone is an antiarrhythmic medication that is not indicated as an initial treatment for acute myocardial infarction unless there are accompanying life-threatening arrhythmias.</li><li>\u2022 Option A. Amiodarone:</li><li>\u2022 antiarrhythmic medication</li><li>\u2022 not</li><li>\u2022 acute</li><li>\u2022 myocardial infarction</li><li>\u2022 life-threatening arrhythmias.</li><li>\u2022 Option B. Adenosine: Adenosine is typically used in the treatment of certain forms of supraventricular tachycardia and not in the setting of acute myocardial infarction.</li><li>\u2022 Option B. Adenosine:</li><li>\u2022 used</li><li>\u2022 supraventricular tachycardia</li><li>\u2022 not</li><li>\u2022 acute myocardial infarction.</li><li>\u2022 Option D. Verapamil: Verapamil is a calcium channel blocker that is generally contraindicated in the setting of acute myocardial infarction, especially with evidence of STEMI, as it can further depress myocardial contractility and lead to hemodynamic deterioration.</li><li>\u2022 Option D. Verapamil:</li><li>\u2022 calcium channel blocker</li><li>\u2022 contraindicated</li><li>\u2022 acute myocardial</li><li>\u2022 infarction,</li><li>\u2022 STEMI,</li><li>\u2022 depress myocardial contractility</li><li>\u2022 lead to hemodynamic</li><li>\u2022 deterioration.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The objective is to recognize the appropriate use of thrombolytic therapy in the treatment of STEMI when PCI is not immediately available. Prompt initiation of thrombolytic therapy can significantly improve outcomes in STEMI by restoring coronary blood flow and minimizing myocardial damage.</li><li>\u27a4 appropriate use of thrombolytic therapy</li><li>\u27a4 STEMI when PCI is not immediately</li><li>\u27a4 available.</li><li>\u27a4 Prompt</li><li>\u27a4 thrombolytic therapy</li><li>\u27a4 improve outcomes in STEMI</li><li>\u27a4 coronary blood flow</li><li>\u27a4 minimizing myocardial damage.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "59173095",
      "audio": ""
    },
    {
      "text": "Drug obtained from plant (shown in the Figure) is used for treatment of? Myocardial infarction Malaria Congestive heart failure Arrhythmias",
      "options": [
        {
          "label": "A",
          "text": "a & b",
          "correct": false
        },
        {
          "label": "B",
          "text": "b & c",
          "correct": false
        },
        {
          "label": "C",
          "text": "c & d",
          "correct": false
        },
        {
          "label": "D",
          "text": "b & d",
          "correct": true
        }
      ],
      "correct_answer": "D. b & d",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/03/30/picture4_rOVLeTF.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) b & d</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Myocardial infarction: Neither quinine nor quinidine is primarily used for the treatment of myocardial infarction.</li><li>\u2022 Option A. Myocardial infarction:</li><li>\u2022 quinine nor quinidine</li><li>\u2022 myocardial infarction.</li><li>\u2022 Option B. Malaria: Quinine , obtained from the cinchona bark , is indeed used for the treatment of malaria.</li><li>\u2022 Option B. Malaria:</li><li>\u2022 Quinine</li><li>\u2022 cinchona bark</li><li>\u2022 treatment of malaria.</li><li>\u2022 Option C. Congestive heart failure: Neither quinine nor quinidine is a first-line treatment for congestive heart failure.</li><li>\u2022 Option C. Congestive heart failure:</li><li>\u2022 Neither quinine nor quinidine</li><li>\u2022 first-line</li><li>\u2022 congestive heart failure.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Quinine and quinidine, drugs derived from the cinchona plant, are used in the treatment of malaria and cardiac arrhythmias, respectively, illustrating the importance of plant-based compounds in the development of medications.</li><li>\u27a4 Quinine and quinidine,</li><li>\u27a4 cinchona plant,</li><li>\u27a4 malaria and cardiac arrhythmias,</li><li>\u27a4 importance of plant-based compounds</li><li>\u27a4 development of medications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3e84554f",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is used for reversal of cerebral vasospasm and infarct following subarachnoid hemorrhage?",
      "options": [
        {
          "label": "A",
          "text": "Nimodipine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Amlodipine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Diltiazem",
          "correct": false
        },
        {
          "label": "D",
          "text": "Verapamil",
          "correct": false
        }
      ],
      "correct_answer": "A. Nimodipine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Nimodipine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Amlodipine: While amlodipine is also a calcium channel blocker , it is not specifically indicated for cerebral vasospasm. It is more commonly used for hypertension and coronary artery disease.</li><li>\u2022 Option B. Amlodipine:</li><li>\u2022 calcium channel blocker</li><li>\u2022 cerebral vasospasm.</li><li>\u2022 hypertension and coronary artery disease.</li><li>\u2022 Option C. Diltiazem: Diltiazem is another calcium channel blocker with a broader cardiovascular effect profile and is not the drug of choice for cerebral vasospasm.</li><li>\u2022 Option C. Diltiazem:</li><li>\u2022 calcium channel blocker</li><li>\u2022 broader cardiovascular effect profile</li><li>\u2022 not</li><li>\u2022 cerebral vasospasm.</li><li>\u2022 Option D. Verapamil: Verapamil is a non-selective calcium channel blocker and is not specifically recommended for the treatment of cerebral vasospasm following subarachnoid hemorrhage.</li><li>\u2022 Option D. Verapamil:</li><li>\u2022 non-selective calcium channel blocker</li><li>\u2022 not</li><li>\u2022 cerebral vasospasm</li><li>\u2022 subarachnoid hemorrhage.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Nimodipine is used for the reversal of cerebral vasospasm and reducing mortality after subarachnoid hemorrhage, due to its s elective action on cerebral blood vessels.</li><li>\u27a4 Nimodipine</li><li>\u27a4 reversal of cerebral vasospasm and reducing mortality</li><li>\u27a4 subarachnoid hemorrhage,</li><li>\u27a4 elective action on cerebral blood vessels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "44ad5601",
      "audio": ""
    },
    {
      "text": "Antihypertensive drugs act by all the following mechanism except?",
      "options": [
        {
          "label": "A",
          "text": "Na + - K + - ATPase inhibition",
          "correct": true
        },
        {
          "label": "B",
          "text": "Alpha adrenergic blockade",
          "correct": false
        },
        {
          "label": "C",
          "text": "Beta adrenergic blockade",
          "correct": false
        },
        {
          "label": "D",
          "text": "Potassium channel opener",
          "correct": false
        }
      ],
      "correct_answer": "A. Na + - K + - ATPase inhibition",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Na+- K+- ATPase inhibition</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The Na+- K+- ATPase inhibition mechanism is associated with digitalis drugs for CHF and not with the treatment of hypertension, whereas alpha and beta adrenergic blockade and potassium channel opening are valid mechanisms for antihypertensive drugs.</li><li>\u27a4 Na+- K+- ATPase inhibition</li><li>\u27a4 digitalis drugs for CHF</li><li>\u27a4 not</li><li>\u27a4 hypertension,</li><li>\u27a4 alpha and beta adrenergic blockade and potassium channel opening</li><li>\u27a4 antihypertensive drugs.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9f60ad58",
      "audio": ""
    },
    {
      "text": "In a patient with concomitant diabetes, anti-hypertensive agent of choice is?",
      "options": [
        {
          "label": "A",
          "text": "Thiazides",
          "correct": false
        },
        {
          "label": "B",
          "text": "Beta adrenergic blocker",
          "correct": false
        },
        {
          "label": "C",
          "text": "ACE inhibitor",
          "correct": true
        },
        {
          "label": "D",
          "text": "Diazoxide",
          "correct": false
        }
      ],
      "correct_answer": "C. ACE inhibitor",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) ACE inhibitor</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Thiazides: Thiazide diuretics are effective antihypertensive agents but can affect carbohydrate metabolism and are not the first choice in patients with diabetes , as they can potentially worsen glycemic control.</li><li>\u2022 Option A. Thiazides:</li><li>\u2022 antihypertensive</li><li>\u2022 affect carbohydrate metabolism</li><li>\u2022 not</li><li>\u2022 first choice in patients with diabetes</li><li>\u2022 worsen glycemic control.</li><li>\u2022 Option B. Beta adrenergic blocker: Beta-blockers can mask symptoms of hypoglycemia and may also affect lipid metabolism. Although they are effective for blood pressure control, they are not typically the first-line choice in diabetic patients unless there are other compelling indications such as heart failure or post-myocardial infarction.</li><li>\u2022 Option B. Beta adrenergic blocker:</li><li>\u2022 can mask</li><li>\u2022 hypoglycemia</li><li>\u2022 lipid metabolism.</li><li>\u2022 effective for blood pressure control,</li><li>\u2022 not</li><li>\u2022 first-line choice in diabetic patients</li><li>\u2022 other compelling indications such as heart failure or post-myocardial infarction.</li><li>\u2022 Option D. Diazoxide: Diazoxide is a vasodilator that can actually increase blood sugar levels by inhibiting insulin release from the pancreas . It is not used for routine treatment of hypertension and is certainly not the drug of choice in patients with diabetes.</li><li>\u2022 Option D. Diazoxide:</li><li>\u2022 vasodilator</li><li>\u2022 increase blood sugar levels</li><li>\u2022 inhibiting insulin release</li><li>\u2022 pancreas</li><li>\u2022 not</li><li>\u2022 hypertension</li><li>\u2022 not the drug of choice in patients with diabetes.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the appropriate choice of antihypertensive medication in patients with diabetes . ACE inhibitors offer renal protection and do not worsen glycemic control, making them a superior option for this patient population. Other properties of ACE inhibitors are also important for entrance exams.</li><li>\u27a4 appropriate choice of antihypertensive medication in patients with diabetes</li><li>\u27a4 ACE</li><li>\u27a4 inhibitors offer renal protection</li><li>\u27a4 do not</li><li>\u27a4 glycemic control,</li><li>\u27a4 Properties of ACE inhibitors</li><li>\u27a4 Properties of ACE inhibitors</li><li>\u27a4 C - C ough</li><li>\u27a4 C</li><li>\u27a4 C</li><li>\u27a4 A - A ngioedema</li><li>\u27a4 A</li><li>\u27a4 A</li><li>\u27a4 P - P rodrugs (except captopril and Lisinopril)</li><li>\u27a4 P</li><li>\u27a4 P</li><li>\u27a4 T - T aste disturbances</li><li>\u27a4 T</li><li>\u27a4 T</li><li>\u27a4 O - O rthostatic hypotension (when combined with diuretics)</li><li>\u27a4 O</li><li>\u27a4 O</li><li>\u27a4 P - P regnancy (contra- indicated)</li><li>\u27a4 P</li><li>\u27a4 P</li><li>\u27a4 R - bilateral R enal artery stenosis (contra-indicated)</li><li>\u27a4 R</li><li>\u27a4 R</li><li>\u27a4 I - I ncreased K+ (contra-indicated)</li><li>\u27a4 I</li><li>\u27a4 I</li><li>\u27a4 L - L ower the risk of diabetic nephropathy (Preferred drug in diabetic patients with hypertension)</li><li>\u27a4 L</li><li>\u27a4 L</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5624d58f",
      "audio": ""
    },
    {
      "text": "Which of the following is a Rho kinase inhibitor?",
      "options": [
        {
          "label": "A",
          "text": "Fasudil",
          "correct": true
        },
        {
          "label": "B",
          "text": "Ranolazine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Trimetazidine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ivabradine",
          "correct": false
        }
      ],
      "correct_answer": "A. Fasudil",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Fasudil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Ranolazine: Ranolazine is an anti-anginal medication. It works by inhibiting the late phase of the sodium current in the cardiac myocytes , thus reducing intracellular calcium overload and myocardial oxygen consumption. It does not act as a Rho kinase inhibitor.</li><li>\u2022 Option B. Ranolazine:</li><li>\u2022 anti-anginal medication.</li><li>\u2022 inhibiting the late phase of the sodium</li><li>\u2022 cardiac myocytes</li><li>\u2022 reducing intracellular calcium overload</li><li>\u2022 myocardial oxygen consumption.</li><li>\u2022 does not</li><li>\u2022 Rho kinase</li><li>\u2022 inhibitor.</li><li>\u2022 Option C. Trimetazidine: Trimetazidine is an anti-ischemic (anti-anginal) metabolic agent that improves myocardial glucose utilization through inhibition of fatty acid metabolism. This action helps to maintain energy production in ischemic heart cells. Trimetazidine is not a Rho kinase inhibitor.</li><li>\u2022 Option C. Trimetazidine:</li><li>\u2022 anti-ischemic (anti-anginal) metabolic agent</li><li>\u2022 improves myocardial glucose</li><li>\u2022 inhibition of fatty acid metabolism.</li><li>\u2022 maintain energy production in ischemic heart cells.</li><li>\u2022 Trimetazidine is not a Rho kinase inhibitor.</li><li>\u2022 Option D. Ivabradine: Ivabradine is a heart rate-reducing agent that works by inhibiting the If (funny) channel in the sinoatrial node of the heart , leading to a reduction in heart rate and myocardial oxygen demand. It is used for the treatment of chronic heart failure and stable angina pectoris in patients who cannot take beta-blockers . Ivabradine is not a Rho kinase inhibitor.</li><li>\u2022 Option D. Ivabradine:</li><li>\u2022 heart rate-reducing agent</li><li>\u2022 inhibiting the If (funny) channel in the sinoatrial node</li><li>\u2022 of the heart</li><li>\u2022 reduction in heart rate and myocardial oxygen demand.</li><li>\u2022 chronic heart failure</li><li>\u2022 stable angina pectoris</li><li>\u2022 cannot take beta-blockers</li><li>\u2022 Ivabradine is not a Rho kinase inhibitor.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the different mechanisms of action of various anti-anginal drugs. Fasudil as a Rho kinase inhibitor contrasts with ranolazine, trimetazidine, and ivabradine, which have different mechanisms.</li><li>\u27a4 different mechanisms of action</li><li>\u27a4 anti-anginal drugs. Fasudil as a Rho kinase</li><li>\u27a4 inhibitor contrasts</li><li>\u27a4 ranolazine, trimetazidine, and ivabradine,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2e3dd569",
      "audio": ""
    },
    {
      "text": "Identify the antiarrhythmic agent with the following mechanism of action?",
      "options": [
        {
          "label": "A",
          "text": "Flecainide",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tocainide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Procainamide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ibutilide",
          "correct": false
        }
      ],
      "correct_answer": "A. Flecainide",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/02/14/whatsapp-image-2024-02-14-at-35057-pm.jpeg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/image-3-1.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Flecainide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Tocainide: Tocainide is a Class IB antiarrhythmic agent. Class IB drugs tend to shorten the action potential duration rather than having no change in repolarization.</li><li>\u2022 Option B. Tocainide:</li><li>\u2022 Class IB antiarrhythmic agent.</li><li>\u2022 shorten the action potential</li><li>\u2022 no change in repolarization.</li><li>\u2022 Option C. Procainamide: Procainamide is a Class IA antiarrhythmic agent that not only blocks sodium channels but also has a moderate effect on repolarization, leading to a slight prolongation of the action potential, which is not depicted in the graph.</li><li>\u2022 Option C. Procainamide:</li><li>\u2022 a Class IA antiarrhythmic agent</li><li>\u2022 not only blocks sodium channels</li><li>\u2022 moderate effect on repolarization,</li><li>\u2022 slight prolongation of the action potential,</li><li>\u2022 Option D. Ibutilide: Ibutilide is a Class III antiarrhythmic drug that acts by prolonging repolarization through potassium channel blockade, which would lengthen the action potential, contrary to what is shown in the graph.</li><li>\u2022 Option D. Ibutilide:</li><li>\u2022 Class III antiarrhythmic drug</li><li>\u2022 prolonging repolarization</li><li>\u2022 potassium channel</li><li>\u2022 blockade,</li><li>\u2022 lengthen the action potential,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to recognize the electrophysiologic profiles of different classes of antiarrhythmic drugs. Class IC antiarrhythmics like flecainide are characterized by their potent sodium channel-blocking effects with minimal impact on the duration of the action potential. Understanding these properties is important for the appropriate selection and use of antiarrhythmic drugs in clinical practice.</li><li>\u27a4 electrophysiologic profiles</li><li>\u27a4 different classes of antiarrhythmic drugs.</li><li>\u27a4 Class IC</li><li>\u27a4 antiarrhythmics like flecainide</li><li>\u27a4 potent sodium channel-blocking effects</li><li>\u27a4 minimal impact</li><li>\u27a4 duration of the action potential.</li><li>\u27a4 appropriate selection and use of antiarrhythmic drugs in clinical practice.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "74cdabd5",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT true about the use of \u03b2 blockers in CHF?",
      "options": [
        {
          "label": "A",
          "text": "These should be started at a very low dose and slowly titrated upwards",
          "correct": false
        },
        {
          "label": "B",
          "text": "Carvedilol is the most widely used \u03b2 blocker",
          "correct": false
        },
        {
          "label": "C",
          "text": "These are drug of choice in acute decompensated heart failure",
          "correct": true
        },
        {
          "label": "D",
          "text": "These can reduce mortality in CHF patients",
          "correct": false
        }
      ],
      "correct_answer": "C. These are drug of choice in acute decompensated heart failure",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) These are drug of choice in acute decompensated heart failure</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. These should be started at a very low dose and slowly titrated upwards: This is correct and a key principle in the chronic management of CHF . Beta blockers need to be started at low doses to avoid abrupt changes in cardiac function and allow for patient tolerance.</li><li>\u2022 Option A. These should be started at a very low dose and slowly titrated upwards:</li><li>\u2022 correct</li><li>\u2022 chronic</li><li>\u2022 CHF</li><li>\u2022 low doses to avoid abrupt changes in cardiac function</li><li>\u2022 Option B. Carvedilol is the most widely used \u03b2 blocker: While carvedilol is one of the commonly used beta blockers in CHF, saying it is \" the most widely used \" may not be true in all settings, as metoprolol and bisoprolol are also commonly prescribed. However, this statement is generally accepted in practice.</li><li>\u2022 Option B. Carvedilol is the most widely used \u03b2 blocker:</li><li>\u2022 carvedilol</li><li>\u2022 beta blockers in CHF,</li><li>\u2022 the most widely used</li><li>\u2022 not be true in all settings,</li><li>\u2022 metoprolol and bisoprolol</li><li>\u2022 also commonly prescribed.</li><li>\u2022 Option D. These can reduce mortality in CHF patients: This is true . Beta blockers have been shown to decrease mortality in chronic CHF by improving left ventricular function , reducing arrhythmias, and limiting cardiac remodeling.</li><li>\u2022 Option D. These can reduce mortality in CHF patients:</li><li>\u2022 true</li><li>\u2022 Beta blockers</li><li>\u2022 decrease mortality in chronic</li><li>\u2022 CHF</li><li>\u2022 improving left ventricular function</li><li>\u2022 reducing arrhythmias, and limiting cardiac remodeling.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Beta blockers should not be used as the drug of choice in acute decompensated heart failure but are essential for the management of chronic CHF , where they have been shown to reduce mortality and morbidity.</li><li>\u27a4 Beta blockers</li><li>\u27a4 not</li><li>\u27a4 drug of choice</li><li>\u27a4 acute decompensated heart failure</li><li>\u27a4 chronic CHF</li><li>\u27a4 reduce mortality and morbidity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "38063111",
      "audio": ""
    },
    {
      "text": "All the following drugs can cause gynecomastia except:",
      "options": [
        {
          "label": "A",
          "text": "Digoxin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Amiloride",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cimetidine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ketoconazole",
          "correct": false
        }
      ],
      "correct_answer": "B. Amiloride",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Amiloride</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Digoxin: Digoxin, a cardiac glycoside, has been associated with gynecomastia as a rare adverse effect, possibly due to its estrogen-like effects and alterations in hormone metabolism.</li><li>\u2022 Option A. Digoxin:</li><li>\u2022 Digoxin,</li><li>\u2022 cardiac glycoside,</li><li>\u2022 gynecomastia</li><li>\u2022 adverse effect,</li><li>\u2022 estrogen-like effects and alterations in hormone metabolism.</li><li>\u2022 Option C. Cimetidine: Cimetidine, a histamine H2 receptor antagonist , can cause gynecomastia by blocking androgen receptors and increasing prolactin secretion.</li><li>\u2022 Option C. Cimetidine:</li><li>\u2022 histamine H2 receptor antagonist</li><li>\u2022 gynecomastia</li><li>\u2022 blocking androgen receptors</li><li>\u2022 increasing prolactin secretion.</li><li>\u2022 Option D. Ketoconazole: Ketoconazole, an antifungal agent, can inhibit testosterone synthesis by blocking cytochrome P450 enzymes, leading to elevated estrogen levels and resulting in gynecomastia.</li><li>\u2022 Option D. Ketoconazole:</li><li>\u2022 an antifungal agent,</li><li>\u2022 inhibit testosterone synthesis</li><li>\u2022 blocking cytochrome P450</li><li>\u2022 elevated estrogen levels</li><li>\u2022 gynecomastia.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to recognize medications associated with the development of gynecomastia a s an adverse effect.</li><li>\u27a4 recognize medications associated with the development of gynecomastia a</li><li>\u27a4 IMPORTANT DRUGS CAUSING GYNAECOMASTIA:</li><li>\u27a4 IMPORTANT DRUGS CAUSING GYNAECOMASTIA:</li><li>\u27a4 DI: DI goxin</li><li>\u27a4 DI: DI</li><li>\u27a4 S: S pironolactone</li><li>\u27a4 S: S</li><li>\u27a4 C: C imetidine, K etoconazole</li><li>\u27a4 C: C</li><li>\u27a4 K</li><li>\u27a4 O: O estrogens</li><li>\u27a4 O: O</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6064dc48",
      "audio": ""
    },
    {
      "text": "Which of the following drug precipitates digoxin toxicity by inhibiting the efflux proteins (P-glycoprotein) of digoxin?",
      "options": [
        {
          "label": "A",
          "text": "Calcium gluconate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Quinidine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Propranolol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tricyclic antidepressants",
          "correct": false
        }
      ],
      "correct_answer": "B. Quinidine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Quinidine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Calcium gluconate: Calcium gluconate is not known to inhibit P-gp and does not precipitate digoxin toxicity.</li><li>\u2022 Option A. Calcium gluconate:</li><li>\u2022 not known</li><li>\u2022 inhibit P-gp</li><li>\u2022 does not</li><li>\u2022 digoxin toxicity.</li><li>\u2022 Option C. Propranolol: Propranolol is a beta-blocker and d oes not inhibit P-gp. It may increase the risk of digoxin toxicity through additive negative chronotropic and dromotropic effects.</li><li>\u2022 Option C. Propranolol:</li><li>\u2022 beta-blocker</li><li>\u2022 oes not inhibit P-gp.</li><li>\u2022 increase the risk of digoxin toxicity</li><li>\u2022 negative chronotropic and dromotropic effects.</li><li>\u2022 Option D. Tricyclic antidepressants: Tricyclic antidepressants are not known to inhibit P-gp and do not directly precipitate digoxin toxicity.</li><li>\u2022 Option D. Tricyclic antidepressants:</li><li>\u2022 not known to inhibit P-gp</li><li>\u2022 do not</li><li>\u2022 digoxin</li><li>\u2022 toxicity.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to know the important drug interactions that can precipitate digoxin toxicity.</li><li>\u27a4 drug interactions</li><li>\u27a4 digoxin toxicity.</li><li>\u27a4 Interactions of digoxin:</li><li>\u27a4 Interactions of digoxin:</li><li>\u27a4 Diuretics : Cause hypokalemia which increases the risk of digitalis arrhythmias: potassium supplements should be given prophylactically. Calcium : Synergies with digitalis and thus precipitates toxicity. Quinidine : Reduces its renal and biliary clearance by inhibiting efflux transporter P-glycoprotein leading to increase in plasma concentration of digoxin. Verapamil, clarithromycin and amiodarone also increase plasma concentration of digoxin to variable extents.</li><li>\u27a4 Diuretics : Cause hypokalemia which increases the risk of digitalis arrhythmias: potassium supplements should be given prophylactically.</li><li>\u27a4 Diuretics</li><li>\u27a4 hypokalemia</li><li>\u27a4 increases the risk of digitalis arrhythmias: potassium supplements</li><li>\u27a4 prophylactically.</li><li>\u27a4 Calcium : Synergies with digitalis and thus precipitates toxicity.</li><li>\u27a4 Calcium</li><li>\u27a4 Synergies with digitalis</li><li>\u27a4 precipitates toxicity.</li><li>\u27a4 Quinidine : Reduces its renal and biliary clearance by inhibiting efflux transporter P-glycoprotein leading to increase in plasma concentration of digoxin. Verapamil, clarithromycin and amiodarone also increase plasma concentration of digoxin to variable extents.</li><li>\u27a4 Quinidine</li><li>\u27a4 Reduces its renal and biliary clearance</li><li>\u27a4 inhibiting efflux transporter P-glycoprotein</li><li>\u27a4 increase in</li><li>\u27a4 plasma concentration of digoxin.</li><li>\u27a4 Verapamil, clarithromycin and amiodarone</li><li>\u27a4 increase plasma concentration of digoxin to variable extents.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e8582e83",
      "audio": ""
    },
    {
      "text": "All the following drugs are likely to produce the following ECG abnormality except:",
      "options": [
        {
          "label": "A",
          "text": "Procainamide",
          "correct": false
        },
        {
          "label": "B",
          "text": "Flecanide",
          "correct": true
        },
        {
          "label": "C",
          "text": "Quinidine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sotalol",
          "correct": false
        }
      ],
      "correct_answer": "B. Flecanide",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/49.jpg"
      ],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/08/screenshot-2024-05-08-123410.png"
      ],
      "explanation": "<p><strong>Ans. B) Flecainide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Procainamide: Procainamide is a Class Ia antiarrhythmic that can block cardiac potassium channels , which may lead to QT prolongation and the potential development of Torsades de pointes.</li><li>\u2022 Option A. Procainamide:</li><li>\u2022 Class Ia antiarrhythmic</li><li>\u2022 block cardiac potassium channels</li><li>\u2022 QT prolongation</li><li>\u2022 Torsades de pointes.</li><li>\u2022 Option C. Quinidine: Quinidine, also a Class Ia antiarrhythmic, has similar effects on potassium channels and can cause QT prolongation and Torsades de pointes.</li><li>\u2022 Option C. Quinidine:</li><li>\u2022 Class Ia antiarrhythmic,</li><li>\u2022 potassium channels</li><li>\u2022 QT</li><li>\u2022 prolongation and Torsades de pointes.</li><li>\u2022 Option D. Sotalol: Sotalol is a Class III antiarrhythmic that can cause QT prolongation and is known to be associated with the risk of Torsades de pointes.</li><li>\u2022 Option D. Sotalol:</li><li>\u2022 Class III antiarrhythmic</li><li>\u2022 QT prolongation</li><li>\u2022 risk of</li><li>\u2022 Torsades de pointes.</li><li>\u2022 Flecainide, a Class Ic antiarrhythmic , primarily affects sodium channels and is less likely to cause QT prolongation, making it less likely to be associated with Torsades de pointes compared to the other drugs listed.</li><li>\u2022 Flecainide, a Class Ic antiarrhythmic</li><li>\u2022 sodium channels</li><li>\u2022 less likely</li><li>\u2022 QT prolongation,</li><li>\u2022 less</li><li>\u2022 Torsades de pointes</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Flecainide , a Class Ic antiarrhythmic drug, is unlikely to cause QT prolongation and Torsades de pointes compared to Class Ia and III drugs, which can prolong the QT interval and are implicated in this arrhythmia.</li><li>\u27a4 Flecainide</li><li>\u27a4 Class Ic antiarrhythmic</li><li>\u27a4 unlikely to cause QT prolongation</li><li>\u27a4 Torsades de pointes</li><li>\u27a4 compared to Class Ia and III</li><li>\u27a4 prolong the QT interval</li><li>\u27a4 arrhythmia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "217cc553",
      "audio": ""
    },
    {
      "text": "All the following about the use of spironolactone in congestive heart failure are true except?",
      "options": [
        {
          "label": "A",
          "text": "It should be given in low doses to prevent hyperkalemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "It affords prognostic benefit in severe heart failure over and above ACEI",
          "correct": false
        },
        {
          "label": "C",
          "text": "It helps to overcome refractoriness to loop diuretics",
          "correct": false
        },
        {
          "label": "D",
          "text": "It affords rapid symptomatic relief in CHF patients",
          "correct": true
        }
      ],
      "correct_answer": "D. It affords rapid symptomatic relief in CHF patients",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) It affords rapid symptomatic relief in CHF patients</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It should be given in low doses to prevent hyperkalemia.</li><li>\u2022 Option A.</li><li>\u2022 It should be given in low doses to prevent hyperkalemia.</li><li>\u2022 This statement is true. Spironolactone is a potassium-sparing diuretic , and one of its potential side effects is hyperkalemia (high blood potassium levels). Therefore, it is typically started at a low dose to minimize this risk.</li><li>\u2022 This statement is true. Spironolactone is a potassium-sparing diuretic , and one of its potential side effects is hyperkalemia (high blood potassium levels). Therefore, it is typically started at a low dose to minimize this risk.</li><li>\u2022 true.</li><li>\u2022 potassium-sparing diuretic</li><li>\u2022 hyperkalemia (high blood potassium levels).</li><li>\u2022 low dose to minimize this risk.</li><li>\u2022 Option B. It affords prognostic benefit in severe HF over and above ACEI.</li><li>\u2022 Option B.</li><li>\u2022 It affords prognostic benefit in severe HF over and above ACEI.</li><li>\u2022 This statement is true . Spironolactone has been shown to provide a prognostic benefit in patients with severe heart failure, reducing morbidity and mortality when added to standard therapy, including ACE inhibitors (ACEIs).</li><li>\u2022 This statement is true . Spironolactone has been shown to provide a prognostic benefit in patients with severe heart failure, reducing morbidity and mortality when added to standard therapy, including ACE inhibitors (ACEIs).</li><li>\u2022 true</li><li>\u2022 prognostic benefit</li><li>\u2022 severe heart</li><li>\u2022 failure, reducing morbidity and mortality</li><li>\u2022 standard therapy, including ACE inhibitors (ACEIs).</li><li>\u2022 Option C. It helps to overcome refractoriness to loop diuretics.</li><li>\u2022 Option C.</li><li>\u2022 It helps to overcome refractoriness to loop diuretics.</li><li>\u2022 This statement is true . Spironolactone can be used in combination with loop diuretics to overcome diuretic resistance in CHF . L oop diuretics can lead to increased renal potassium and magnesium loss, and adding a potassium-sparing agent like spironolactone can help counteract this effect and enhance diuretic response.</li><li>\u2022 This statement is true . Spironolactone can be used in combination with loop diuretics to overcome diuretic resistance in CHF . L oop diuretics can lead to increased renal potassium and magnesium loss, and adding a potassium-sparing agent like spironolactone can help counteract this effect and enhance diuretic response.</li><li>\u2022 true</li><li>\u2022 combination with loop diuretics</li><li>\u2022 diuretic resistance</li><li>\u2022 CHF</li><li>\u2022 oop diuretics</li><li>\u2022 increased renal potassium and magnesium loss,</li><li>\u2022 potassium-sparing agent</li><li>\u2022 spironolactone</li><li>\u2022 counteract this effect and enhance diuretic response.</li><li>\u2022 Current evidence suggests the following regarding aldosterone receptor antagonist (spironolactone and eplerenone) therapy in CHF:</li><li>\u2022 Current evidence suggests the following regarding aldosterone receptor antagonist (spironolactone and eplerenone) therapy in CHF:</li><li>\u2022 It is indicated as add-on therapy to ACE inhibitors + other drugs in moderate-to-severe CHF. It can retard disease progression, reduce episodes of decompensation and death due to heart failure as well as sudden c ardiac deaths , over and above the protection afforded by ACE inhibitors/ARBs \u00b1 \u03b2 blockers. Only low doses (12.5\u201325 mg/day) of spironolactone should be used to avoid hyperkalemia; particularly because of concurrent ACE inhibitor/ARB therapy. It may help restoration of diuretic response to furosemide when refractoriness has developed.</li><li>\u2022 It is indicated as add-on therapy to ACE inhibitors + other drugs in moderate-to-severe CHF.</li><li>\u2022 add-on therapy to ACE inhibitors + other drugs</li><li>\u2022 moderate-to-severe CHF.</li><li>\u2022 It can retard disease progression, reduce episodes of decompensation and death due to heart failure as well as sudden c ardiac deaths , over and above the protection afforded by ACE inhibitors/ARBs \u00b1 \u03b2 blockers.</li><li>\u2022 retard disease progression, reduce episodes of decompensation and death</li><li>\u2022 heart failure</li><li>\u2022 sudden</li><li>\u2022 ardiac deaths</li><li>\u2022 protection afforded by ACE inhibitors/ARBs \u00b1 \u03b2 blockers.</li><li>\u2022 Only low doses (12.5\u201325 mg/day) of spironolactone should be used to avoid hyperkalemia; particularly because of concurrent ACE inhibitor/ARB therapy.</li><li>\u2022 low doses (12.5\u201325 mg/day)</li><li>\u2022 avoid hyperkalemia;</li><li>\u2022 concurrent ACE inhibitor/ARB therapy.</li><li>\u2022 It may help restoration of diuretic response to furosemide when refractoriness has developed.</li><li>\u2022 restoration of diuretic response to furosemide</li><li>\u2022 refractoriness has developed.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b91e0a3f",
      "audio": ""
    },
    {
      "text": "All the following statements about the Nitrates in Angina are true except?",
      "options": [
        {
          "label": "A",
          "text": "Reduce preload",
          "correct": false
        },
        {
          "label": "B",
          "text": "Sildenafil may pronounce hypotension and should never be combined",
          "correct": false
        },
        {
          "label": "C",
          "text": "Cause redistribution of coronary blood flow",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tolerance is most seen in sublingual administration of nitrates",
          "correct": true
        }
      ],
      "correct_answer": "D. Tolerance is most seen in sublingual administration of nitrates",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Tolerance is most seen in sublingual administration of nitrates</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Reduce preload: True . Nitrates predominantly dilate veins, leading to a reduction in preload, which decreases the amount of blood returning to the heart , thereby reducing the work the hear t has to do and the oxygen demand.</li><li>\u2022 Option A. Reduce preload:</li><li>\u2022 True</li><li>\u2022 Nitrates predominantly dilate veins,</li><li>\u2022 reduction in preload,</li><li>\u2022 decreases the amount</li><li>\u2022 blood returning to the heart</li><li>\u2022 reducing the work the hear</li><li>\u2022 do and the oxygen demand.</li><li>\u2022 Option B. Sildenafil may pronounce hypotension and should never be combined: True. Combining nitrates with sildenafil can lead to dangerous potentiation of vasodilatory effects, resulting in severe hypotension, myocardial infarction, and even death.</li><li>\u2022 Option B. Sildenafil may pronounce hypotension and should never be combined:</li><li>\u2022 True.</li><li>\u2022 nitrates with sildenafil</li><li>\u2022 vasodilatory effects,</li><li>\u2022 severe hypotension,</li><li>\u2022 myocardial infarction, and even death.</li><li>\u2022 Option C. Cause redistribution of coronary blood flow: True . Nitrates preferentially dilate larger conducting coronary arteries over arterioles , which may facilitate increased blood flow to ischemic areas of the heart in patients with angina.</li><li>\u2022 Option C. Cause redistribution of coronary blood flow:</li><li>\u2022 True</li><li>\u2022 dilate larger</li><li>\u2022 conducting coronary arteries</li><li>\u2022 arterioles</li><li>\u2022 increased blood flow to ischemic areas of the heart</li><li>\u2022 angina.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the context of angina treatment, nitrates are known to reduce preload and can cause redistribution of coronary blood flow , but significant tolerance is not typically associated with intermittent sublingual administration. It is also critical to avoid the combination of nitrates with sildenafil due to the risk of severe hypotension.</li><li>\u27a4 nitrates</li><li>\u27a4 reduce preload</li><li>\u27a4 redistribution of coronary blood flow</li><li>\u27a4 significant tolerance</li><li>\u27a4 not</li><li>\u27a4 with intermittent sublingual administration.</li><li>\u27a4 avoid the</li><li>\u27a4 combination of nitrates with sildenafil</li><li>\u27a4 risk of severe hypotension.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ac6f8347",
      "audio": ""
    },
    {
      "text": "Cardiac oxygen demand (MVO2) must be reduced in angina pectoris. The therapeutic rationale for using SL nitroglycerine is based on:",
      "options": [
        {
          "label": "A",
          "text": "Reduction of after load",
          "correct": false
        },
        {
          "label": "B",
          "text": "Reduction of heart rate and cardiac MVO2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Reduction of preload and cardiac MVO2",
          "correct": true
        },
        {
          "label": "D",
          "text": "Increase preload with decrease in cardiac MVO2",
          "correct": false
        }
      ],
      "correct_answer": "C. Reduction of preload and cardiac MVO2",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Reduction of preload and cardiac MVO2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Reduction of afterload: While nitroglycerine may have some effect on reducing afterload due to its arterial vasodilatory properties , its primary mechanism of action is the reduction of preload.</li><li>\u2022 Option A. Reduction of afterload:</li><li>\u2022 nitroglycerine</li><li>\u2022 some effect</li><li>\u2022 reducing afterload</li><li>\u2022 arterial vasodilatory</li><li>\u2022 properties</li><li>\u2022 primary mechanism of action</li><li>\u2022 reduction of preload.</li><li>\u2022 Option B. Reduction of heart rate and cardiac MVO2: Nitroglycerine may have a mild effect on heart rate , but its primary mechanism of action is not related to heart rate reduction. It mainly reduces preload, which indirectly decreases cardiac MVO2.</li><li>\u2022 Option B. Reduction of heart rate and cardiac MVO2:</li><li>\u2022 Nitroglycerine</li><li>\u2022 mild effect on heart rate</li><li>\u2022 not related to heart rate reduction.</li><li>\u2022 reduces preload,</li><li>\u2022 indirectly decreases cardiac MVO2.</li><li>\u2022 Option D. Increase preload with decrease in cardiac MVO2: Increasing preload would typically increase cardiac workload and oxygen demand rather than decrease it. This option contradicts the therapeutic rationale for using nitroglycerine in angina pectoris.</li><li>\u2022 Option D. Increase preload with decrease in cardiac MVO2:</li><li>\u2022 Increasing preload</li><li>\u2022 increase cardiac workload and</li><li>\u2022 oxygen demand</li><li>\u2022 decrease it.</li><li>\u2022 contradicts</li><li>\u2022 nitroglycerine in angina pectoris.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the therapeutic rationale for using sublingual nitroglycerine in the management of angina pectoris . By reducing preload, nitroglycerine decreases myocardial oxygen demand, providing symptomatic relief in patients with angina . Understanding the mechanisms of action of nitroglycerine is essential for appropriate prescribing and management of angina episode s.</li><li>\u27a4 therapeutic rationale</li><li>\u27a4 sublingual nitroglycerine</li><li>\u27a4 angina</li><li>\u27a4 pectoris</li><li>\u27a4 reducing preload,</li><li>\u27a4 decreases myocardial oxygen demand,</li><li>\u27a4 providing symptomatic relief</li><li>\u27a4 angina</li><li>\u27a4 mechanisms of action of nitroglycerine</li><li>\u27a4 prescribing and management</li><li>\u27a4 angina episode</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "68b90bd7",
      "audio": ""
    },
    {
      "text": "Which of the following antiarrhythmic drug is contraindicated in a patient with interstitial lung disease?",
      "options": [
        {
          "label": "A",
          "text": "Amiodarone",
          "correct": true
        },
        {
          "label": "B",
          "text": "Sotalol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Quinidine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lignocaine",
          "correct": false
        }
      ],
      "correct_answer": "A. Amiodarone",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Amiodarone</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Sotalol: Sotalol is also a class III antiarrhythmic drug but does not carry the same risk for inducing pulmonary toxicity as amiodarone.</li><li>\u2022 Option B. Sotalol:</li><li>\u2022 class III antiarrhythmic drug</li><li>\u2022 does not</li><li>\u2022 pulmonary toxicity as</li><li>\u2022 amiodarone.</li><li>\u2022 Option C. Quinidine: Quinidine is a class Ia antiarrhythmic drug and is not associated with interstitial lung disease as a side effect.</li><li>\u2022 Option C. Quinidine:</li><li>\u2022 class Ia antiarrhythmic drug</li><li>\u2022 not</li><li>\u2022 interstitial lung disease</li><li>\u2022 Option D. Lignocaine: Lignocaine (lidocaine) is a class Ib antiarrhythmic drug used mainly in acute settings for ventricular arrhythmias and does not have pulmonary toxicity akin to amiodarone.</li><li>\u2022 Option D. Lignocaine:</li><li>\u2022 class Ib antiarrhythmic</li><li>\u2022 acute settings for ventricular</li><li>\u2022 arrhythmias</li><li>\u2022 does not</li><li>\u2022 pulmonary toxicity akin to amiodarone.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Amiodarone, while effective as a broad-spectrum antiarrhythmic agent , is contraindicated in patients with interstitial lung disease because of its serious side effect of pulmonary alveolitis and fibrosis.</li><li>\u27a4 Amiodarone,</li><li>\u27a4 broad-spectrum antiarrhythmic agent</li><li>\u27a4 contraindicated in patients</li><li>\u27a4 interstitial lung disease</li><li>\u27a4 side effect of pulmonary alveolitis and fibrosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b0af007f",
      "audio": ""
    },
    {
      "text": "Which of the following drugs block late inward sodium ion channels?",
      "options": [
        {
          "label": "A",
          "text": "Ranolazine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Trimetazidine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ivabradine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fasudil",
          "correct": false
        }
      ],
      "correct_answer": "A. Ranolazine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Ranolazine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Trimetazidine: Trimetazidine acts as a partial fatty acid oxidation inhibitor, optimizing the energy metabolism of the heart during ischemia, but it does not block sodium channels.</li><li>\u2022 Option B. Trimetazidine:</li><li>\u2022 Option C. Ivabradine: Ivabradine selectively inhibits the funny current (If) in the sinoatrial node, resulting in heart rate reduction, which can be beneficial in conditions like angina and heart failure, but it is not a sodium channel blocker.</li><li>\u2022 Option C. Ivabradine:</li><li>\u2022 Option D. Fasudil: Fasudil is a Rho-kinase inhibitor with vasodilatory effects and does not block sodium channels.</li><li>\u2022 Option D. Fasudil:</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ranolazine is a late inward sodium channel blocker that can be used to treat chronic angina by improving myocardial relaxation and decreasing ischemia without major effects on heart rate or blood pressure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "82633a83",
      "audio": ""
    },
    {
      "text": "The side-effect of which of the following drug is used as a therapeutic advantage in alopecia?",
      "options": [
        {
          "label": "A",
          "text": "Hydralazine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Diazoxide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Minoxidil",
          "correct": true
        },
        {
          "label": "D",
          "text": "Nicorandil",
          "correct": false
        }
      ],
      "correct_answer": "C. Minoxidil",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Minoxidil</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hydralazine: Hydralazine is an antihypertensive medication that does not have a therapeutic advantage in alopecia. It does not promote hair growth and is not used in the treatment of alopecia.</li><li>\u2022 Option A. Hydralazine:</li><li>\u2022 antihypertensive</li><li>\u2022 does not</li><li>\u2022 alopecia.</li><li>\u2022 does not promote hair growth</li><li>\u2022 not</li><li>\u2022 alopecia.</li><li>\u2022 Option B. Diazoxide: Diazoxide is a medication used to treat hypoglycemia and hypertensive emergencies . It is not associated with any therapeutic advantage in alopecia.</li><li>\u2022 Option B. Diazoxide:</li><li>\u2022 treat hypoglycemia and hypertensive emergencies</li><li>\u2022 not</li><li>\u2022 alopecia.</li><li>\u2022 Option D. Nicorandil: Nicorandil is a vasodilator medication used to treat angina pectoris. It does not have a therapeutic advantage in alopecia and is not used for this purpose.</li><li>\u2022 Option D. Nicorandil:</li><li>\u2022 vasodilator medication</li><li>\u2022 angina pectoris.</li><li>\u2022 does not</li><li>\u2022 alopecia</li><li>\u2022 not</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the therapeutic use of minoxidil in the treatment of alopecia and how its side effect of promoting hair growth is exploited for this purpose . Recognizing medications with beneficial side effects allows clinicians to repurpose drugs for new indications and optimize patient care.</li><li>\u27a4 therapeutic use of minoxidil</li><li>\u27a4 alopecia</li><li>\u27a4 side effect of</li><li>\u27a4 promoting hair growth</li><li>\u27a4 exploited for this purpose</li><li>\u27a4 beneficial side effects allows clinicians to repurpose drugs for new indications and optimize patient care.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e8753865",
      "audio": ""
    },
    {
      "text": "A 52-year-old patient with a history of coronary artery disease and hyperlipidemia presents to the clinic for a routine follow-up. The patient is currently on atorvastatin for LDL cholesterol management but has recently had a lipid panel showing elevated Lipoprotein (a) levels. The patient is interested in exploring medication options that could specifically target the reduction of Lipoprotein (a) levels. Which of the following drugs is most likely to result in a reduction of Lipoprotein (a) levels?",
      "options": [
        {
          "label": "A",
          "text": "Rosuvastatin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Fenofibrate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Evolocumab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Niacin",
          "correct": true
        }
      ],
      "correct_answer": "D. Niacin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Niacin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Rosuvastatin: Statins like rosuvastatin are primarily known for their ability to lower LDL cholesterol but have a less pronounced effect on Lipoprotein (a).</li><li>\u2022 Option A. Rosuvastatin:</li><li>\u2022 Statins</li><li>\u2022 their ability to lower LDL cholesterol</li><li>\u2022 less</li><li>\u2022 Lipoprotein (a).</li><li>\u2022 Option B. Fenofibrate: Fenofibrate is used for its potent triglyceride-lowering effects and does not have a significant impact on Lipoprotein (a) levels.</li><li>\u2022 Option B. Fenofibrate:</li><li>\u2022 potent triglyceride-lowering effects</li><li>\u2022 does not</li><li>\u2022 Lipoprotein (a) levels.</li><li>\u2022 Option C. Evolocumab: Evolocumab, a PCSK9 inhibitor, primarily lowers LDL cholesterol and has a relatively mild effect on reducing Lipoprotein (a) levels compared to niacin.</li><li>\u2022 Option C. Evolocumab:</li><li>\u2022 PCSK9 inhibitor,</li><li>\u2022 lowers LDL cholesterol</li><li>\u2022 mild effect on reducing</li><li>\u2022 Lipoprotein (a) levels</li><li>\u2022 niacin.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Niacin is a lipid-lowering agent that can significantly reduce levels of Lipoprotein (a), distinguishing it from other lipid-modifying therapies that primarily focus on lowering LDL cholesterol or triglycerides.</li><li>\u27a4 Niacin is a lipid-lowering agent</li><li>\u27a4 reduce levels of Lipoprotein (a),</li><li>\u27a4 lipid-modifying</li><li>\u27a4 primarily focus on lowering LDL cholesterol or triglycerides.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9fafd491",
      "audio": ""
    },
    {
      "text": "Which of the following is a direct renin inhibitor?",
      "options": [
        {
          "label": "A",
          "text": "Aliskiren",
          "correct": true
        },
        {
          "label": "B",
          "text": "Losartan",
          "correct": false
        },
        {
          "label": "C",
          "text": "Perindopril",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vernakalant",
          "correct": false
        }
      ],
      "correct_answer": "A. Aliskiren",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Aliskiren</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Losartan: Losartan is an angiotensin II receptor blocker (ARB), which works further downstream in the RAAS pathway by blocking the angiotensin II type 1 receptors on blood vessels, leading to vasodilation.</li><li>\u2022 Option B. Losartan:</li><li>\u2022 angiotensin II receptor blocker (ARB),</li><li>\u2022 downstream in the RAAS pathway</li><li>\u2022 blocking the angiotensin II type 1 receptors on blood vessels,</li><li>\u2022 vasodilation.</li><li>\u2022 Option C. Perindopril: Perindopril is an angiotensin-converting enzyme (ACE) inhibitor . It prevents the conversion of angiotensin I to angiotensin II by inhibiting the ACE enzyme.</li><li>\u2022 Option C. Perindopril:</li><li>\u2022 angiotensin-converting enzyme (ACE) inhibitor</li><li>\u2022 prevents</li><li>\u2022 angiotensin I to</li><li>\u2022 angiotensin II</li><li>\u2022 ACE enzyme.</li><li>\u2022 Option D. Vernakalant: Vernakalant is not related to the RAAS pathway ; it is a class III antiarrhythmic agent that acts as a multiple ion channel blocke r, particularly affecting atrial cells, and is used to treat certain types of arrhythmias.</li><li>\u2022 Option D. Vernakalant:</li><li>\u2022 not</li><li>\u2022 RAAS pathway</li><li>\u2022 class III antiarrhythmic agent</li><li>\u2022 multiple</li><li>\u2022 ion channel blocke</li><li>\u2022 atrial cells,</li><li>\u2022 types of arrhythmias.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Aliskiren is the only direct renin inhibitor among the options listed, acting at the rate-limiting step of the RAAS pathway by inhibiting the conversion of angiotensinogen to angiotensin I.</li><li>\u27a4 Aliskiren</li><li>\u27a4 renin inhibitor</li><li>\u27a4 rate-limiting step of the RAAS pathway</li><li>\u27a4 inhibiting the conversion of angiotensinogen to angiotensin I.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "527c1dc1",
      "audio": ""
    },
    {
      "text": "Which of the following antihypertensive drug is avoided in patients with high serum uric acid levels?",
      "options": [
        {
          "label": "A",
          "text": "Hydrochlorothiazide",
          "correct": true
        },
        {
          "label": "B",
          "text": "Atenolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Prazosin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Enalapril",
          "correct": false
        }
      ],
      "correct_answer": "A. Hydrochlorothiazide",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Hydrochlorothiazide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Atenolol: Atenolol is a cardioselective beta-blocker that does not directly affect serum uric acid levels . It is not contraindicated in patients with high uric acid levels.</li><li>\u2022 Option B. Atenolol:</li><li>\u2022 cardioselective beta-blocker</li><li>\u2022 serum uric acid levels</li><li>\u2022 not</li><li>\u2022 contraindicated in patients</li><li>\u2022 high uric acid levels.</li><li>\u2022 Option C. Prazosin : Prazosin is an alpha-1 adrenergic antagonist that does not affect serum uric acid levels . It is not contraindicated in patients with hyperuricemia.</li><li>\u2022 Option C. Prazosin</li><li>\u2022 alpha-1 adrenergic antagonist</li><li>\u2022 does not</li><li>\u2022 uric acid levels</li><li>\u2022 hyperuricemia.</li><li>\u2022 Option D. Enalapril : Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that does not significantly affect serum uric acid levels. It is generally considered safe for use in patients with high uric acid levels.</li><li>\u2022 Option D.</li><li>\u2022 Enalapril</li><li>\u2022 angiotensin-converting enzyme (ACE) inhibitor</li><li>\u2022 does not</li><li>\u2022 serum uric acid</li><li>\u2022 high uric acid levels.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to understand the association between antihypertensive medications and serum uric acid levels . Thiazide diuretics like hydrochlorothiazide can increase serum uric acid levels and are typically avoided in patients with hyperuricemia or a history of gout.</li><li>\u27a4 antihypertensive medications and serum uric acid levels</li><li>\u27a4 Thiazide diuretics</li><li>\u27a4 hydrochlorothiazide</li><li>\u27a4 increase serum uric acid levels</li><li>\u27a4 avoided in patients</li><li>\u27a4 hyperuricemia or a history of gout.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a888fa4d",
      "audio": ""
    },
    {
      "text": "The anticonvulsant agent useful as an antiarrhythmic belongs to which class of antiarrhythmic drug?",
      "options": [
        {
          "label": "A",
          "text": "Class Ia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Class Ib",
          "correct": true
        },
        {
          "label": "C",
          "text": "Class Ic",
          "correct": false
        },
        {
          "label": "D",
          "text": "Class II",
          "correct": false
        }
      ],
      "correct_answer": "B. Class Ib",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Class Ib</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Class Ia antiarrhythmics: Drugs in this class, such as quinidine and procainamide , block sodium channels and prolong the action potential duration . While effective in treating arrhythmias, they are not commonly used as anticonvulsants.</li><li>\u2022 Option A. Class Ia antiarrhythmics:</li><li>\u2022 such as quinidine and procainamide</li><li>\u2022 block sodium channels</li><li>\u2022 action potential duration</li><li>\u2022 treating arrhythmias,</li><li>\u2022 not</li><li>\u2022 anticonvulsants.</li><li>\u2022 Option C. Class Ic antiarrhythmics: These drugs, including flecainide and propafenone, also block sodium channels but have minimal effects on action potential duration . They are primarily used for supraventricular arrhythmias and are not typically used as anticonvulsants.</li><li>\u2022 Option C. Class Ic antiarrhythmics:</li><li>\u2022 including flecainide and propafenone,</li><li>\u2022 block sodium channels</li><li>\u2022 minimal effects on action potential duration</li><li>\u2022 supraventricular arrhythmias</li><li>\u2022 not</li><li>\u2022 anticonvulsants.</li><li>\u2022 Option D. Class II antiarrhythmics: Class II drugs are beta-adrenergic blockers , such as propranolol and metoprolol, which reduce sympathetic stimulation of the heart . While they may have indirect effects on certain arrhythmias, they are not commonly used as anticonvulsants.</li><li>\u2022 Option D. Class II antiarrhythmics:</li><li>\u2022 beta-adrenergic blockers</li><li>\u2022 propranolol and metoprolol,</li><li>\u2022 reduce</li><li>\u2022 sympathetic stimulation of the heart</li><li>\u2022 indirect effects on certain arrhythmias,</li><li>\u2022 not</li><li>\u2022 anticonvulsants.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Understanding the classification of antiarrhythmic drugs and their mechanisms of action is crucial for selecting appropriate medications for the treatment of various arrhythmia s. Additionally, recognizing the dual utility of certain medications, like phenytoin, as both anticonvulsants and antiarrhythmics, enhances clinical decision-making in patients with overlapping conditions.</li><li>\u27a4 classification of antiarrhythmic drugs</li><li>\u27a4 their mechanisms of action</li><li>\u27a4 selecting appropriate</li><li>\u27a4 medications</li><li>\u27a4 various arrhythmia</li><li>\u27a4 dual utility of certain medications,</li><li>\u27a4 phenytoin, as both anticonvulsants and antiarrhythmics,</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "04f7ee10",
      "audio": ""
    },
    {
      "text": "A 33-year-old man is diagnosed with essential hypertension. He is started on an anti-hypertensive medication. After 6 weeks, he notes fatigue, rash over his face, joint aches, and effusions. A serum antinuclear antibody (ANA) test is positive. Which of the following is the most likely agent person was prescribed?",
      "options": [
        {
          "label": "A",
          "text": "Hydralazine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Propranolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Thiazide diuretic",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nifedipine",
          "correct": false
        }
      ],
      "correct_answer": "A. Hydralazine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Hydralazine</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Hydralazine is associated with the development of a lupus-like syndrome, which is characterized by symptoms such as rash, joint pain, fatigue, and positive ANA, and it is one of the drugs that can induce this condition, summarized by the acronym \"SHIP\" for sulfonamides, hydralazine, isoniazid, and procainamide.</li><li>\u27a4 Hydralazine</li><li>\u27a4 development of a lupus-like syndrome,</li><li>\u27a4 rash, joint</li><li>\u27a4 pain, fatigue, and positive ANA,</li><li>\u27a4 one of the drugs</li><li>\u27a4 induce</li><li>\u27a4 \"SHIP\"</li><li>\u27a4 sulfonamides, hydralazine, isoniazid, and procainamide.</li><li>\u27a4 The drugs causing SLE like syndrome include:</li><li>\u27a4 SLE like syndrome</li><li>\u27a4 S: S ulfonamides (including dapsone) H: H ydralazine I: I soniazid P: P rocainamide All SHIP drugs are metabolized by acetylation.</li><li>\u27a4 S: S ulfonamides (including dapsone)</li><li>\u27a4 S: S</li><li>\u27a4 H: H ydralazine</li><li>\u27a4 H: H</li><li>\u27a4 I: I soniazid</li><li>\u27a4 I: I</li><li>\u27a4 P: P rocainamide All SHIP drugs are metabolized by acetylation.</li><li>\u27a4 P: P</li><li>\u27a4 All SHIP drugs are metabolized by acetylation.</li><li>\u27a4 All SHIP drugs are metabolized by acetylation.</li><li>\u27a4 SHIP drugs</li><li>\u27a4 metabolized by acetylation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0b5a3686",
      "audio": ""
    },
    {
      "text": "A 45-year-old patient presented with the symptoms shown in the image below. Patient is a known hypertensive and was taking some antihypertensive drug. Which of the following drug is the likely cause of this condition?",
      "options": [
        {
          "label": "A",
          "text": "Lisinopril",
          "correct": true
        },
        {
          "label": "B",
          "text": "Clonidine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Nifedipine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Timolol",
          "correct": false
        }
      ],
      "correct_answer": "A. Lisinopril",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/25/51.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Lisinopril</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Clonidine: Clonidine, a centrally acting alpha-2 adrenergic agonist, is not typically associated with angioedema . Its main adverse effects include dry mouth, sedation, and rebound hypertension if discontinued abruptly.</li><li>\u2022 Option B. Clonidine:</li><li>\u2022 centrally acting alpha-2 adrenergic agonist,</li><li>\u2022 not</li><li>\u2022 angioedema</li><li>\u2022 dry mouth, sedation, and rebound hypertension</li><li>\u2022 discontinued abruptly.</li><li>\u2022 Option C. Nifedipine: Nifedipine is a calcium channel blocker that primarily dilates arterial vessels and is commonly used to treat hypertension and angina . Angioedema is not a typical side effect of nifedipine.</li><li>\u2022 Option C. Nifedipine:</li><li>\u2022 calcium channel blocker</li><li>\u2022 primarily dilates arterial vessels</li><li>\u2022 hypertension and angina</li><li>\u2022 Angioedema is not</li><li>\u2022 side effect</li><li>\u2022 Option D. Timolol: Timolol is a non-selective beta-adrenergic blocker used to treat hypertension, angina, and glaucoma. While beta blockers can rarely cause angioedema , it is not a common side effect associated with timolol.</li><li>\u2022 Option D. Timolol:</li><li>\u2022 non-selective beta-adrenergic blocker</li><li>\u2022 hypertension, angina, and glaucoma.</li><li>\u2022 beta</li><li>\u2022 blockers</li><li>\u2022 angioedema</li><li>\u2022 not</li><li>\u2022 side effect</li><li>\u2022 timolol.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Angioedema is a rare but potentially serious adverse effect of ACE inhibitors like lisinopril. Recognizing this adverse reaction is essential for prompt discontinuation of the offending medication and initiation of appropriate management to prevent complications.</li><li>\u27a4 Angioedema</li><li>\u27a4 rare</li><li>\u27a4 serious adverse effect</li><li>\u27a4 ACE inhibitors</li><li>\u27a4 lisinopril.</li><li>\u27a4 prompt discontinuation of the offending medication</li><li>\u27a4 initiation of appropriate management to prevent</li><li>\u27a4 complications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "84f34c97",
      "audio": ""
    },
    {
      "text": "A patient on digoxin therapy had a level of 1 ng/ml. He was receiving several other drugs and presented 2 months later with flattening of T waves in ECG. Now the plasma level of digoxin is 3.8 ng/ml. Which of the following drug is likely to be responsible?",
      "options": [
        {
          "label": "A",
          "text": "Triamterene",
          "correct": false
        },
        {
          "label": "B",
          "text": "Atenolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Clarithromycin",
          "correct": true
        },
        {
          "label": "D",
          "text": "KCI",
          "correct": false
        }
      ],
      "correct_answer": "C. Clarithromycin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Clarithromycin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Triamterene: Triamterene is a potassium-sparing diuretic that can increase digoxin levels by reducing its renal clearance. However, the extent of increase observed in this case is less commonly associated with triamterene.</li><li>\u2022 Option A. Triamterene:</li><li>\u2022 potassium-sparing diuretic</li><li>\u2022 increase digoxin levels</li><li>\u2022 reducing its renal clearance.</li><li>\u2022 extent of increase</li><li>\u2022 less</li><li>\u2022 triamterene.</li><li>\u2022 Option B. Atenolol: Atenolol, a beta-blocker, can increase digoxin levels by delaying its elimination . However, the degree of increase seen here is less characteristic of atenolol's interaction with digoxin.</li><li>\u2022 Option B. Atenolol:</li><li>\u2022 beta-blocker,</li><li>\u2022 increase digoxin levels</li><li>\u2022 delaying its elimination</li><li>\u2022 degree of increase</li><li>\u2022 Option D. KCl: Potassium chloride supplementation can potentiate the effects of digoxin , potentially leading to toxicity. However, it typically does not cause such a significant increase in digoxin levels.</li><li>\u2022 Option D. KCl:</li><li>\u2022 Potassium chloride supplementation</li><li>\u2022 digoxin</li><li>\u2022 toxicity.</li><li>\u2022 does not</li><li>\u2022 increase in digoxin levels.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Recognizing drug interactions that impact digoxin levels is crucial for preventing digoxin toxicity in patients receiving concurrent therapy . Vigilance and close monitoring of digoxin levels are essential to ensure patient safety.</li><li>\u27a4 drug interactions</li><li>\u27a4 digoxin levels</li><li>\u27a4 preventing digoxin toxicity</li><li>\u27a4 concurrent</li><li>\u27a4 therapy</li><li>\u27a4 Vigilance</li><li>\u27a4 close monitoring of digoxin levels</li><li>\u27a4 patient safety.</li><li>\u27a4 INTERACTIONS OF DIGOXIN</li><li>\u27a4 INTERACTIONS OF DIGOXIN</li><li>\u27a4 Hypokalemia, hypomagnesemia, and hypercalcemia may precipitate digoxin toxicity. Drugs causing digoxin toxicity include:</li><li>\u27a4 Hypokalemia, hypomagnesemia, and hypercalcemia may precipitate digoxin toxicity.</li><li>\u27a4 Hypokalemia, hypomagnesemia, and hypercalcemia</li><li>\u27a4 Drugs causing digoxin toxicity include:</li><li>\u27a4 causing digoxin</li><li>\u27a4 toxicity</li><li>\u27a4 Quinidine Verapamil Amiodarone Thiazides Clarithromycin</li><li>\u27a4 Quinidine</li><li>\u27a4 Verapamil</li><li>\u27a4 Amiodarone</li><li>\u27a4 Thiazides</li><li>\u27a4 Clarithromycin</li><li>\u27a4 Renal failure predisposes to digoxin toxicity.</li><li>\u27a4 Renal failure predisposes to digoxin toxicity.</li><li>\u27a4 Renal failure</li><li>\u27a4 digoxin toxicity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7b35a8a9",
      "audio": ""
    },
    {
      "text": "A 26-year-old female came to hospital for preconception counseling. Patient is a known hypertensive compliant to drug therapy. Which of the following drugs will you advise to stop?",
      "options": [
        {
          "label": "A",
          "text": "Methyldopa",
          "correct": false
        },
        {
          "label": "B",
          "text": "Labetalol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lisinopril",
          "correct": true
        },
        {
          "label": "D",
          "text": "Nifedipine",
          "correct": false
        }
      ],
      "correct_answer": "C. Lisinopril",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Lisinopril</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Methyldopa: Methyldopa is commonly used in pregnancy for hypertension and is considered safe. It is often continued during pregnancy if the patient is well-controlled.</li><li>\u2022 Option A. Methyldopa:</li><li>\u2022 commonly used in pregnancy for hypertension</li><li>\u2022 safe.</li><li>\u2022 well-controlled.</li><li>\u2022 Option B. Labetalol: Labetalol is another antihypertensive agent commonly used during pregnancy . It has a good safety profile and is often continued if the patient is well-controlled.</li><li>\u2022 Option B. Labetalol:</li><li>\u2022 antihypertensive agent</li><li>\u2022 during pregnancy</li><li>\u2022 good safety profile</li><li>\u2022 patient is well-controlled.</li><li>\u2022 Option D. Nifedipine: Nifedipine is also considered safe for use during pregnancy and is commonly prescribed for hypertension in pregnant women.</li><li>\u2022 Option D. Nifedipine:</li><li>\u2022 safe for use during pregnancy</li><li>\u2022 prescribed for hypertension</li><li>\u2022 pregnant women.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Understanding the safety profiles of antihypertensive medications during pregnancy is essential for preconception counseling. Lisinopril is contraindicated during pregnancy due to its association with fetal malformations, particularly during the second and third trimesters . It is important to discontinue potentially harmful medications before conception to minimize risks to both the mother and the developing fetus.</li><li>\u27a4 safety profiles of antihypertensive medications</li><li>\u27a4 pregnancy</li><li>\u27a4 preconception counseling.</li><li>\u27a4 Lisinopril is contraindicated during pregnancy</li><li>\u27a4 fetal malformations,</li><li>\u27a4 second and</li><li>\u27a4 third trimesters</li><li>\u27a4 discontinue</li><li>\u27a4 harmful medications before conception</li><li>\u27a4 minimize risks to both</li><li>\u27a4 mother and the developing fetus.</li><li>\u27a4 SAFE ANTI-HYPERTENSIVES IN PREGNANCY</li><li>\u27a4 SAFE ANTI-HYPERTENSIVES IN PREGNANCY</li><li>\u27a4 B etter              - B eta blockers (Cardio selective and Labetalol) M other            - Methyldopa C are                 - C lonidine D uring             - D ihydropyridine CCB (sustained release nifedipine, amlodipine) H ypertensive   - H ydralazine P regnancy       - P razosin (and other alpha blockers)</li><li>\u27a4 B etter              - B eta blockers (Cardio selective and Labetalol)</li><li>\u27a4 B</li><li>\u27a4 B</li><li>\u27a4 M other            - Methyldopa</li><li>\u27a4 M</li><li>\u27a4 Methyldopa</li><li>\u27a4 C are                 - C lonidine</li><li>\u27a4 C</li><li>\u27a4 C</li><li>\u27a4 D uring             - D ihydropyridine CCB (sustained release nifedipine, amlodipine)</li><li>\u27a4 D</li><li>\u27a4 D</li><li>\u27a4 H ypertensive   - H ydralazine</li><li>\u27a4 H</li><li>\u27a4 H</li><li>\u27a4 P regnancy       - P razosin (and other alpha blockers)</li><li>\u27a4 P</li><li>\u27a4 P</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b130ad72",
      "audio": ""
    },
    {
      "text": "Which of the following antihypertensive drug has a central sympatholytic action?",
      "options": [
        {
          "label": "A",
          "text": "Levodopa",
          "correct": false
        },
        {
          "label": "B",
          "text": "Carbidopa",
          "correct": false
        },
        {
          "label": "C",
          "text": "Alpha methyl dopa",
          "correct": true
        },
        {
          "label": "D",
          "text": "Hydralazine",
          "correct": false
        }
      ],
      "correct_answer": "C. Alpha methyl dopa",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Alpha methyl dopa</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Levodopa : Levodopa is not an antihypertensive drug; it is primarily used in the treatment of Parkinson's disease to replenish dopamine levels in the brain.</li><li>\u2022 Option A. Levodopa</li><li>\u2022 not</li><li>\u2022 antihypertensive drug;</li><li>\u2022 Parkinson's disease to</li><li>\u2022 replenish dopamine levels</li><li>\u2022 Option B. Carbidopa : Carbidopa is often co-administered with levodopa to enhance its therapeutic effects in Parkinson's disease . It does not have antihypertensive properties.</li><li>\u2022 Option B. Carbidopa</li><li>\u2022 co-administered with levodopa</li><li>\u2022 enhance its therapeutic effects</li><li>\u2022 Parkinson's disease</li><li>\u2022 does not</li><li>\u2022 antihypertensive properties.</li><li>\u2022 Option D. Hydralazine : Hydralazine is a direct-acting vasodilator that primarily acts on arterial smooth muscle to decrease peripheral resistance and lower blood pressure. It does not exert its effects through central sympatholytic mechanisms.</li><li>\u2022 Option D. Hydralazine</li><li>\u2022 direct-acting vasodilator</li><li>\u2022 acts on arterial smooth muscle to decrease peripheral</li><li>\u2022 resistance and lower blood pressure.</li><li>\u2022 does not</li><li>\u2022 central sympatholytic mechanisms.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Understanding the mechanisms of action of different antihypertensive drugs is important for selecting appropriate medications based on the patient's condition and comorbidities . Alpha-methyl dopa is a centrally acting antihypertensive agent that reduces sympathetic outflow from the brainstem, leading to vasodilation and decreased blood pressure.</li><li>\u27a4 mechanisms of action of different antihypertensive drugs</li><li>\u27a4 selecting appropriate medications</li><li>\u27a4 patient's condition and comorbidities</li><li>\u27a4 Alpha-methyl dopa</li><li>\u27a4 centrally acting antihypertensive agent</li><li>\u27a4 reduces</li><li>\u27a4 sympathetic outflow</li><li>\u27a4 brainstem, leading to vasodilation and decreased blood pressure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2741053b",
      "audio": ""
    },
    {
      "text": "Inotropic drugs act by stimulating which of the following receptors?",
      "options": [
        {
          "label": "A",
          "text": "Alpha 1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Alpha 2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Beta 1",
          "correct": true
        },
        {
          "label": "D",
          "text": "Beta 2",
          "correct": false
        }
      ],
      "correct_answer": "C. Beta 1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Beta 1</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the mechanism of action of different inotropic drugs.</li><li>\u27a4 mechanism of action</li><li>\u27a4 inotropic drugs.</li><li>\u27a4 INOTROPICS DRUGS</li><li>\u27a4 INOTROPICS DRUGS</li><li>\u27a4 Beta 1 agonists</li><li>\u27a4 Beta 1 agonists</li><li>\u27a4 Beta 1 agonists</li><li>\u27a4 Dopamine Dobutamine Nor-adrenaline Isoprenaline</li><li>\u27a4 Dopamine</li><li>\u27a4 Dobutamine</li><li>\u27a4 Nor-adrenaline</li><li>\u27a4 Isoprenaline</li><li>\u27a4 Phosphodiesterase inhibitors</li><li>\u27a4 Phosphodiesterase inhibitors</li><li>\u27a4 Phosphodiesterase inhibitors</li><li>\u27a4 Inamrinone Milrinone Levosimendan</li><li>\u27a4 Inamrinone</li><li>\u27a4 Milrinone</li><li>\u27a4 Levosimendan</li><li>\u27a4 Cardiac glycosides</li><li>\u27a4 Cardiac glycosides</li><li>\u27a4 Cardiac glycosides</li><li>\u27a4 Digoxin Digitoxin (withdrawn now)</li><li>\u27a4 Digoxin</li><li>\u27a4 Digitoxin (withdrawn now)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "86e778cd",
      "audio": ""
    },
    {
      "text": "A patient of Prinzmetal\u2019s angina is started on isosorbide mono nitrate. What is the mechanism of action of nitrates in this condition?",
      "options": [
        {
          "label": "A",
          "text": "Reduced cardiac contractility",
          "correct": false
        },
        {
          "label": "B",
          "text": "Increased left ventricular end diastolic volume",
          "correct": false
        },
        {
          "label": "C",
          "text": "Decreased diastolic perfusion pressure",
          "correct": false
        },
        {
          "label": "D",
          "text": "Endothelium independent coronary vasodilatation",
          "correct": true
        }
      ],
      "correct_answer": "D. Endothelium independent coronary vasodilatation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Endothelium independent coronary vasodilatation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Reduced cardiac contractility: Incorrect as nitrates do not primarily act by reducing the contractility of the heart.</li><li>\u2022 Option A. Reduced cardiac contractility:</li><li>\u2022 Incorrect</li><li>\u2022 nitrates do not</li><li>\u2022 reducing the contractility of the heart.</li><li>\u2022 Option B. Increased left ventricular end diastolic volume: Incorrect because nitrates do not typically increase left ventricular end-diastolic volume; they reduce preload and afterload through vasodilation.</li><li>\u2022 Option B. Increased left ventricular end diastolic volume:</li><li>\u2022 Incorrect</li><li>\u2022 nitrates do not</li><li>\u2022 increase left ventricular end-diastolic volume;</li><li>\u2022 reduce preload and afterload</li><li>\u2022 vasodilation.</li><li>\u2022 Option C. Decreased diastolic perfusion pressure: Incorrect as nitrates do not reduce diastolic perfusion pressure; their action is aimed at reducing vasospasm and increasing perfusion.</li><li>\u2022 Option C. Decreased diastolic perfusion pressure:</li><li>\u2022 Incorrect</li><li>\u2022 nitrates do not reduce diastolic perfusion pressure;</li><li>\u2022 reducing vasospasm and increasing perfusion.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 In Prinzmetal\u2019s angina, nitrates like isosorbide mononitrate work by causing endothelium independent coronary vasodilation, acting directly on the vascular smooth muscle through NO donation, which leads to pain relief by reversing the coronary vasospasm.</li><li>\u2022 Prinzmetal\u2019s angina,</li><li>\u2022 isosorbide mononitrate</li><li>\u2022 causing endothelium independent coronary vasodilation,</li><li>\u2022 vascular smooth muscle through NO donation,</li><li>\u2022 leads to pain relief</li><li>\u2022 reversing the coronary vasospasm.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0c6f6fab",
      "audio": ""
    },
    {
      "text": "Which of the following is the mechanism of action of ezetimibe for the treatment of hypercholesterolemia?",
      "options": [
        {
          "label": "A",
          "text": "Inhibition of HMG-CoA reductase",
          "correct": false
        },
        {
          "label": "B",
          "text": "Inhibition of cholesterol absorption in the small intestine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Inhibition of bile acid synthesis in the liver",
          "correct": false
        },
        {
          "label": "D",
          "text": "Inhibition of lipoprotein lipase activity",
          "correct": false
        }
      ],
      "correct_answer": "B. Inhibition of cholesterol absorption in the small intestine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Inhibition of cholesterol absorption in the small intestine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Inhibition of HMG-CoA reductase: This is the mechanism of action for statins, not ezetimibe. Statins inhibit the rate- l imiting step in cholesterol synthesis in the liver.</li><li>\u2022 Option A. Inhibition of HMG-CoA reductase:</li><li>\u2022 statins, not ezetimibe. Statins inhibit the rate-</li><li>\u2022 imiting step in cholesterol synthesis in the liver.</li><li>\u2022 Option C. Inhibition of bile acid synthesis in the liver: Bile acid sequestrants work by this mechanism. They bind bile acids in the intestine, leading to increased excretion of cholesterol in the feces.</li><li>\u2022 Option C. Inhibition of bile acid synthesis in the liver:</li><li>\u2022 Bile acid sequestrants</li><li>\u2022 bile acids</li><li>\u2022 intestine,</li><li>\u2022 increased excretion of cholesterol in the feces.</li><li>\u2022 Option D. Inhibition of lipoprotein lipase activity: Inhibiting lipoprotein lipase would prevent the breakdown of triglycerides, not cholesterol. This is not a mechanism associated with ezetimibe.</li><li>\u2022 Option D. Inhibition of lipoprotein lipase activity:</li><li>\u2022 Inhibiting lipoprotein lipase</li><li>\u2022 breakdown of triglycerides,</li><li>\u2022 not a mechanism</li><li>\u2022 ezetimibe.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Ezetimibe reduces LDL cholesterol by inhibiting the absorption of cholesterol in the small intestine through its action on the NPC1L1 protein.</li><li>\u27a4 Ezetimibe</li><li>\u27a4 reduces LDL cholesterol by inhibiting the absorption of cholesterol</li><li>\u27a4 NPC1L1</li><li>\u27a4 protein.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2cbe2f9a",
      "audio": ""
    },
    {
      "text": "Which of the following patients should be treated with either an angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker?",
      "options": [
        {
          "label": "A",
          "text": "A 24-year-old woman with type 1 diabetes with two positive spot microalbuminuria tests 1 week apart",
          "correct": false
        },
        {
          "label": "B",
          "text": "A 32-year-old woman with type 1 diabetes with a blood glucose of 328 mg/dL and a positive spot microalbuminuria test",
          "correct": false
        },
        {
          "label": "C",
          "text": "A 48-year-old man with type 2 diabetes with a positive spot microalbuminuria test 1 week after starting a new exercise program",
          "correct": false
        },
        {
          "label": "D",
          "text": "A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart",
          "correct": true
        }
      ],
      "correct_answer": "D. A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) A 56-year-old man with type 2 diabetes with two positive spot microalbuminuria tests 3 months apart</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. The testing interval of 1 week is too soon for confirmation of persistent microalbuminuria.</li><li>\u2022 Option A.</li><li>\u2022 interval of 1 week</li><li>\u2022 persistent microalbuminuria.</li><li>\u2022 Option B. The presence of severe hyperglycemia can transiently increase albumin excretion , potentially confounding the test result.</li><li>\u2022 Option B.</li><li>\u2022 severe hyperglycemia</li><li>\u2022 transiently increase albumin excretion</li><li>\u2022 test result.</li><li>\u2022 Option C. Vigorous exercise can also transiently increase albumin excretion, making the test result unreliable.</li><li>\u2022 Option C.</li><li>\u2022 Vigorous exercise</li><li>\u2022 increase albumin excretion,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the management of diabetic nephropathy, ACE inhibitors or ARBs should be initiated in patients with type 2 diabetes who have confirmed persistent microalbuminuria, indicated by at least two positive microalbuminuria tests spaced 3 to 6 months apart, without the influence of confounding factors.</li><li>\u27a4 diabetic nephropathy, ACE inhibitors or ARBs</li><li>\u27a4 type 2 diabetes</li><li>\u27a4 confirmed persistent microalbuminuria,</li><li>\u27a4 at least two positive microalbuminuria tests</li><li>\u27a4 3 to 6 months</li><li>\u27a4 without</li><li>\u27a4 confounding factors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e67097a3",
      "audio": ""
    }
  ]
}